<?xml version="1.0" encoding="utf-8"?>
<Label drug="Caduet" setid="6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6">
<Text><Section name="CONTRAINDICATIONS SECTION" id="34070-3">
Active liver disease (4.1) Women who are pregnant or may become pregnant (4.2) Nursing mothers (4.3)          Atorvastatin is contraindicated in patients with active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels [see Warnings and Precautions 5.2 and Clinical Pharmacology 12.3].          Atorvastatin is contraindicated in women who are pregnant or may become pregnant. Atorvastatin may cause fetal harm when administered to a pregnant woman. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. There are no adequate and well-controlled studies of atorvastatin use during pregnancy; however, in rare reports congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, atorvastatin revealed no evidence of teratogenicity. CADUET should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazard. If the patient becomes pregnant while taking this drug, therapy should be discontinued immediately and the patient apprised of the potential hazard to the fetus [see Specific Populations (8.1)].          It is not known whether atorvastatin or amlodipine are excreted into human milk; however, a small amount of another statin does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women taking CADUET should not breastfeed their infants [see Specific Populations (8.3)].</Section>
<Section name="DOSAGE &amp;amp; ADMINISTRATION SECTION" id="34068-7">
Usual starting dose(mg daily) Maximum dose(mg daily)     Amlodipine 5Start small adults or children, fragile, or elderly patients, or patients with hepatic insufficiency on 2.5 mg once daily (2)  10   Atorvastatin 10–20Start patients requiring large LDL-C reduction (&amp;gt;45%) at 40 mg once daily (2)  80             CADUET  Dosage of CADUET must be individualized on the basis of both effectiveness and tolerance for each individual component in the treatment of hypertension/angina and hyperlipidemia. Select doses of amlodipine and atorvastatin independently. CADUET may be substituted for its individually titrated components. Patients may be given the equivalent dose of CADUET or a dose of CADUET with increased amounts of amlodipine, atorvastatin, or both for additional antianginal effects, blood pressure lowering, or lipid-lowering effect. CADUET may be used to provide additional therapy for patients already on one of its components. CADUET may be used to initiate treatment in patients with hyperlipidemia and either hypertension or angina.           Amlodipine  The usual initial antihypertensive oral dose of amlodipine is 5 mg once daily, and the maximum dose is 10 mg once daily. Pediatric (age &amp;gt; 6 years), small adult, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding amlodipine to other antihypertensive therapy. Adjust dosage according to blood pressure goals. In general, wait 7 to 14 days between titration steps. Titration may proceed more rapidly, however, if clinically warranted, provided the patient is assessed frequently.         Angina: The recommended dose of amlodipine for chronic stable or vasospastic angina is 5–10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Most patients will require 10 mg for adequate effect.           Coronary artery disease: The recommended dose range of amlodipine for patients with coronary artery disease is 5–10 mg once daily. In clinical studies, the majority of patients required 10 mg [see Clinical Studies (14.4)].           Pediatrics: The effective antihypertensive oral dose of amlodipine in pediatric patients ages 6–17 years is 2.5 mg to 5 mg once daily. Doses in excess of 5 mg daily have not been studied in pediatric patients [see  Clinical Pharmacology (12.3), Clinical Studies (14.1)].             Atorvastatin (Hyperlipidemia)          Hyperlipidemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types IIa and IIb): The recommended starting dose of atorvastatin is 10 or 20 mg once daily. Patients who require a large reduction in LDL-C (more than 45%) may be started at 40 mg once daily. The dosage range of atorvastatin is 10 to 80 mg once daily. Atorvastatin can be administered as a single dose at any time of the day, with or without food. The starting dose and maintenance doses of atorvastatin should be individualized according to patient characteristics such as goal of therapy and response (see current NCEP Guidelines). After initiation and/or upon titration of atorvastatin, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.           Homozygous Familial Hypercholesterolemia: The dosage range of atorvastatin in patients with homozygous FH is 10 to 80 mg daily. Atorvastatin should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.           Concomitant Lipid-Lowering Therapy: Atorvastatin may be used with bile acid resins. Monitor for signs of myopathy in patients receiving the combination of HMG-CoA reductase inhibitors (statins) and fibrates [see Warnings and Precautions (5.1), Drug Interactions (7)].           Patients with Renal Impairment: Renal disease does not affect the plasma concentrations nor LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary [see Warnings and Precautions (5.1), Clinical Pharmacology (12.3)].            Use with Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors: In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the hepatitis C protease inhibitor (telaprevir), avoid therapy with atorvastatin . In patients with HIV taking lopinavir plus ritonavir, use the lowest necessary dose of atorvastatin. In patients taking clarithromycin, itraconazole, or in patients with HIV taking a combination of saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, limit therapy with atorvastatin to 20 mg, and make appropriate clinical assessment to ensure that the lowest dose necessary of atorvastatin is employed. In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, limit therapy with atorvastatin to 40 mg, and make appropriate clinical assessment to ensure that the lowest dose necessary of atorvastatin is employed [see Warnings and Precautions (5.1), Drug Interactions (7.13)].           Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10–17 years of age): The recommended starting dose of atorvastatin is 10 mg/day; the maximum recommended dose is 20 mg/day (doses greater than 20 mg have not been studied in this patient population). Doses should be individualized according to the recommended goal of therapy [see current NCEP Pediatric Panel Guidelines 1, (References (15), Clinical Pharmacology (12), and Indications and Usage (1.4)]. Adjustments should be made at intervals of 4 weeks or more.</Section>
<Section name="DRUG INTERACTIONS SECTION" id="34073-7">
Data from a drug-drug interaction study involving 10 mg of amlodipine and 80 mg of atorvastatin in healthy subjects indicate that the pharmacokinetics of amlodipine are not altered when the drugs are co-administered. The effect of amlodipine on the pharmacokinetics of atorvastatin showed no effect on the Cmax: 91% (90% confidence interval: 80 to 103%), but the AUC of atorvastatin increased by 18% (90% confidence interval: 109 to 127%) in the presence of amlodipine, which is not clinically meaningful. No drug interaction studies have been conducted with CADUET and other drugs, although studies have been conducted in the individual amlodipine and atorvastatin components, as described below:       Increased Risk of Myopathy/Rhabdomyolysis (2, 5.1, 7, 12.3)     Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir) Avoid atorvastatin   Lopinavir plus ritonavir Use lowest dose necessary   Clarithromycin, itraconazole,HIV protease inhibitors (saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir) Do not exceed 20 mg atorvastatin daily   HIV protease inhibitor (nelfinavir)Hepatitis C protease inhibitor (boceprevir) Do not exceed 40 mg atorvastatin daily     Other Lipid-Lowering Medications: Increased risk of myopathy (7). Digoxin: Monitor digoxin levels (7.21). Oral Contraceptives: Norethindrone and ethinyl estradiol may be increased (7.22). Rifampin: Take at same time as CADUET (7.20).           Amlodipine            In vitro data in human plasma indicate that amlodipine has no effect on the protein binding of drugs tested (digoxin, phenytoin, warfarin, and indomethacin).          Co-administration of amlodipine with cimetidine did not alter the pharmacokinetics of amlodipine.          Co-administration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine.          Co-administration of a magnesium and aluminum hydroxide antacid with a single dose of amlodipine had no significant effect on the pharmacokinetics of amlodipine.          A single 100 mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of amlodipine. When amlodipine and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.          Co-administration of multiple 10 mg doses of amlodipine with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.          Co-administration of amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.          Single and multiple 10 mg doses of amlodipine had no significant effect on the pharmacokinetics of ethanol.          Co-administration of amlodipine with warfarin did not change the warfarin prothrombin response time.          Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. Erythromycin co-administration in healthy volunteers did not significantly change amlodipine systemic exposure. However, strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir) may increase the plasma concentrations of amlodipine to a greater extent. Monitor for symptoms of hypotension and edema when amlodipine is co-administered with CYP3A4 inhibitors.          No information is available on the quantitative effects of CYP3A4 inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A4 inducers.          A prospective study in renal transplant patients (N=11) showed on an average of 40% increase in trough cyclosporine levels when concomitantly treated with amlodipine.          None known.         Atorvastatin  The risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].            Atorvastatin is metabolized by CYP3A4. Concomitant administration of atorvastatin with strong inhibitors of CYP3A4 can lead to increases in plasma concentrations of atorvastatin. The extent of interaction and potentiation of effects depend on the variability of effect on CYP3A4.         Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 80 mg with clarithromycin (500 mg twice daily) compared to that of atorvastatin alone [see Clinical Pharmacology (12.3)]. Therefore, in patients taking clarithromycin, avoid atorvastatin doses &amp;gt;20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2)].           Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin with several combinations of HIV protease inhibitors, as well as with the hepatitis C protease inhibitor telaprevir, compared to that of atorvastatin alone [see Clinical Pharmacology (12.3)]. Therefore, in patients taking the HIV protease inhibitor tipranavir plus ritonavir, or the hepatitis C protease inhibitor telaprevir, concomitant use of atorvastatin should be avoided. In patients taking the HIV protease inhibitor lopinavir plus ritonavir, caution should be used when prescribing atorvastatin and the lowest dose necessary should be used. In patients taking the HIV protease inhibitors saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, the dose of atorvastatin should not exceed 20 mg [see Warnings and Precautions (5.1) and Dosage and Administration (2)]. In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, the dose of atorvastatin should not exceed 40 mg and close clinical monitoring is recommended.           Itraconazole : Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)]. Therefore, in patients taking itraconazole, avoid atorvastatin doses &amp;gt;20 mg [see Warnings and Precautions (5.1) and Dosage and Administration (2)].            Contains one or more components that inhibit CYP3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (&amp;gt;1.2 liters per day).          Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter. Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin. Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 10 mg and cyclosporine 5.2 mg/kg/day compared to that of atorvastatin alone [see Clinical Pharmacology (12.3)]. The co-administration of atorvastatin with cyclosporine should be avoided [see Warnings and Precautions (5.1)].          Because of an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are co-administered with gemfibrozil, avoid concomitant administration of atorvastatin with gemfibrozil [see  Warnings and Precautions (5.1) ].          The risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates. [see  Warnings and Precautions (5.1) ].          The risk of skeletal muscle effects may be enhanced when atorvastatin is used in combination with niacin; consider a reduction in atorvastatin dosage in this setting [see  Warnings and Precautions (5.1) ].          Concomitant administration of atorvastatin with inducers of CYP3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin. Because of the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.          When multiple doses of atorvastatin and digoxin were co-administered, steady-state plasma digoxin concentrations increased by approximately 20%. Monitor digoxin levels.          Co-administration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol) [see Clinical Pharmacology (12.3)]. Consider these increases when selecting an oral contraceptive for a woman taking CADUET.          Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.          Cases of myopathy, including rhabdomyolysis, have been reported with atorvastatin co-administered with colchicine.</Section>
<Section name="WARNINGS AND PRECAUTIONS SECTION" id="43685-7">
Myopathy and rhabdomyolysis: Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness. CADUET therapy should be discontinued if myopathy is diagnoses or suspected (5.1, 8.5). Hepatic transaminitis: Monitor liver enzymes before and during treatment (5.2). Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis. However, acute hypotension is unlikely (5.4). Angina or myocardial infarction may occur with initiation or dose increase (5.3).          Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with atorvastatin and with other drugs in this class. A history of renal impairment may be a risk factor for the development of rhabdomyolysis. Such patients merit closer monitoring for skeletal muscle effects. Atorvastatin, like other statins, occasionally causes myopathy, defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values &amp;gt;10 times upper limit of normal [ULN]. The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis. There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement with immunosuppressive agents. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, or marked elevation of CPK. Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing CADUET. CADUET therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. The risk of myopathy during treatment with statins is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, the hepatitis C protease inhibitor telaprevir, combinations of HIV protease inhibitors, including saquinavir plus ritonavir, lopinavir plus ritonavir, tipranavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, and fosamprenavir plus ritonavir, niacin, or azole antifungals. Physicians considering combined therapy with CADUET and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs [see Drug Interactions (7.13)]. Periodic creatine phosphokinase (CPK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe myopathy. Prescribing recommendations for interacting agents are summarized in Table 2 [see also Dosage and Administration (2), Drug Interactions (7.13), Clinical Pharmacology (12.3)].  Table 2. Atorvastatin Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis     Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir) Avoid atorvastatin   HIV protease inhibitor (lopinavir plus ritonavir) Use with caution and lowest dose necessary   Clarithromycin, itraconazole,HIV protease inhibitors (saquinavir plus ritonavirUse with caution and with the lowest dose necessary (12.3), darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir) Do not exceed 20 mg atorvastatin daily   HIV protease inhibitor (nelfinavir)Hepatitis C protease inhibitor (boceprevir) Do not exceed 40 mg atorvastatin daily    Cases of myopathy, including rhabdomyolysis, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine [see Drug Interactions (7.23) ]. Withhold or discontinue in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection; hypotension; major surgery; trauma; severe metabolic, endocrine, and electrolyte disorders; and uncontrolled seizures).          Statins, like atorvastatin, and some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (&amp;gt;3 times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin in clinical trials. The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively. One patient in clinical trials with atorvastatin developed jaundice. Increases in liver function tests (LFT) in other patients were not associated with jaundice or other clinical signs or symptoms. Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae. Eighteen of 30 patients with persistent LFT elevations continued treatment with a reduced dose of atorvastatin. It is recommended that liver enzyme tests be obtained prior to initiating therapy with atorvastatin and repeated as clinically indicated. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including atorvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with CADUET, promptly interrupt therapy. If an alternate etiology is not found, do not restart CADUET. Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of CADUET [see Contraindications (4.1)].          Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of amlodipine, particularly in patients with severe obstructive coronary artery disease.          Symptomatic hypotension is possible with use of amlodipine, particularly in patients with severe aortic stenosis. Because of the gradual onset of action, acute hypotension is unlikely.          Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including atorvastatin. Statins interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production. Clinical studies have shown that atorvastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve. The effects of statins on male fertility have not been studied in adequate numbers of patients. The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown. Avoid a statin with drugs that may decrease the levels or activity of endogenous steroid hormones such as ketoconazole, spironolactone, and cimetidine.          Brain hemorrhage was seen in a female dog treated with atorvastatin for 3 months at 120 mg/kg/day. Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day. The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0–24 hours) based on the maximum human dose of 80 mg/day. A single tonic convulsion was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study. No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day. These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0–24) based on the maximum recommended human dose of 80 mg/day. CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other statins. A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose.          In a post-hoc analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study where atorvastatin 80 mg vs. placebo was administered in 4,731 subjects without CHD who had a stroke or TIA within the preceding 6 months, a higher incidence of hemorrhagic stroke was seen in the atorvastatin 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168). The incidence of fatal hemorrhagic stroke was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively). The incidence of non-fatal hemorrhagic stroke was significantly higher in the atorvastatin group (38, 1.6%) as compared to the placebo group (16, 0.7%). Some baseline characteristics, including hemorrhagic and lacunar stroke on study entry, were associated with a higher incidence of hemorrhagic stroke in the atorvastatin group [see Adverse Reactions (6.1)].</Section>
<Section name="CLINICAL PHARMACOLOGY SECTION" id="34090-1">
CADUET is a combination of two drugs, a dihydropyridine calcium channel blocker (amlodipine) and an HMG-CoA reductase inhibitor (atorvastatin). The amlodipine component of CADUET inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The atorvastatin component of CADUET is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol.         Amlodipine  Amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure. The precise mechanisms by which amlodipine relieves angina have not been fully delineated, but are thought to include the following:         Exertional Angina: In patients with exertional angina, amlodipine reduces the total peripheral resistance (afterload) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise.           Vasospastic Angina: Amlodipine has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels in vitro. This inhibition of coronary spasm is responsible for the effectiveness of amlodipine in vasospastic (Prinzmetal's or variant) angina.             Atorvastatin  Cholesterol and triglycerides circulate in the bloodstream as part of lipoprotein complexes. With ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), IDL (intermediate-density lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions. Triglycerides (TG) and cholesterol in the liver are incorporated into VLDL and released into the plasma for delivery to peripheral tissues. LDL is formed from VLDL and is catabolized primarily through the high-affinity LDL receptor. Clinical and pathologic studies show that elevated plasma levels of total cholesterol (total-C), LDL-cholesterol (LDL-C), and apolipoprotein B (apo B) promote human atherosclerosis and are risk factors for developing cardiovascular disease, while increased levels of HDL-C are associated with a decreased cardiovascular risk. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C, and inversely with the level of HDL-C. In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles. Atorvastatin reduces total-C, LDL-C, and apo B in patients with homozygous and heterozygous familial hypercholesterolemia (FH), nonfamilial forms of hypercholesterolemia, and mixed dyslipidemia. Atorvastatin also reduces VLDL-C and TG and produces variable increases in HDL-C and apolipoprotein A-1. Atorvastatin reduces total-C, LDL-C, VLDL-C, apo B, TG, and non-HDL-C, and increases HDL-C in patients with isolated hypertriglyceridemia. Atorvastatin reduces intermediate density lipoprotein cholesterol (IDL-C) in patients with dysbetalipoproteinemia. Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including VLDL, intermediate density lipoprotein (IDL), and remnants, can also promote atherosclerosis. Elevated plasma triglycerides are frequently found in a triad with low HDL-C levels and small LDL particles, as well as in association with non-lipid metabolic risk factors for coronary heart disease. As such, total plasma TG has not consistently been shown to be an independent risk factor for CHD. Furthermore, the independent effect of raising HDL or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.                  Amlodipine  Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing. Although the acute intravenous administration of amlodipine decreases arterial blood pressure and increases heart rate in hemodynamic studies of patients with chronic stable angina, chronic oral administration of amlodipine in clinical trials did not lead to clinically significant changes in heart rate or blood pressures in normotensive patients with angina. With chronic once daily oral administration, antihypertensive effectiveness is maintained for at least 24 hours. Plasma concentrations correlate with effect in both young and elderly patients. The magnitude of reduction in blood pressure with amlodipine is also correlated with the height of pretreatment elevation; thus, individuals with moderate hypertension (diastolic pressure 105–114 mmHg) had about a 50% greater response than patients with mild hypertension (diastolic pressure 90–104 mmHg). Normotensive subjects experienced no clinically significant change in blood pressures (+1/–2 mmHg). In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal plasma flow without change in filtration fraction or proteinuria. As with other calcium channel blockers, hemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have generally demonstrated a small increase in cardiac index without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In hemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and man, even when co-administered with beta-blockers to man. Similar findings, however, have been observed in normal or well-compensated patients with heart failure with agents possessing significant negative inotropic effects. Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals or man. In patients with chronic stable angina, intravenous administration of 10 mg did not significantly alter A-H and H-V conduction and sinus node recovery time after pacing. Similar results were obtained in patients receiving amlodipine and concomitant beta-blockers. In clinical studies in which amlodipine was administered in combination with beta-blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed. In clinical trials with angina patients alone, amlodipine therapy did not alter electrocardiographic intervals or produce higher degrees of AV blocks.           Atorvastatin  Atorvastatin, as well as some of its metabolites, are pharmacologically active in humans. The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dosage, rather than systemic drug concentration, correlates better with LDL-C reduction. Individualization of drug dosage should be based on therapeutic response [see   Dosage and Administration (2)].                  Absorption          Amlodipine: After oral administration of therapeutic doses of amlodipine alone, absorption produces peak plasma concentrations between 6 and 12 hours. Absolute bioavailability has been estimated to be between 64% and 90%.           Atorvastatin: After oral administration alone, atorvastatin is rapidly absorbed; maximum plasma concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Plasma atorvastatin concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning. However, LDL-C reduction is the same regardless of the time of day of drug administration [see Dosage and Administration (2)].         CADUET: Following oral administration of CADUET, peak plasma concentrations of amlodipine and atorvastatin are seen at 6 to 12 hours and 1 to 2 hours post dosing, respectively. The rate and extent of absorption (bioavailability) of amlodipine and atorvastatin from CADUET are not significantly different from the bioavailability of amlodipine and atorvastatin administered separately (see above). The bioavailability of amlodipine from CADUET was not affected by food. Food decreases the rate and extent of absorption of atorvastatin from CADUET by approximately 32% and 11%, respectively, as it does with atorvastatin when given alone. LDL-C reduction is similar whether atorvastatin is given with or without food.               Distribution          Amlodipine:  Ex vivo studies have shown that approximately 93% of the circulating amlodipine drug is bound to plasma proteins in hypertensive patients. Steady-state plasma levels of amlodipine are reached after 7 to 8 days of consecutive daily dosing.           Atorvastatin: Mean volume of distribution of atorvastatin is approximately 381 liters. Atorvastatin is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells. Based on observations in rats, atorvastatin calcium is likely to be secreted in human milk [see Contraindications (4.3) and Use in Specific Populations (8.3)].             Metabolism          Amlodipine: Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism.           Atorvastatin: Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites.  In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P4503A4, consistent with increased plasma concentrations of atorvastatin in humans following co-administration with erythromycin, a known inhibitor of this isozyme [see Drug Interactions (7.13)]. In animals, the ortho-hydroxy metabolite undergoes further glucuronidation.             Excretion          Amlodipine: Elimination from the plasma is biphasic with a terminal elimination half-life of about 30–50 hours. Ten percent of the parent amlodipine compound and 60% of the metabolites of amlodipine are excreted in the urine.           Atorvastatin: Atorvastatin and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours because of the contribution of active metabolites. Less than 2% of a dose of atorvastatin is recovered in urine following oral administration.             Specific Populations          Geriatric          Amlodipine: Elderly patients have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40–60%, and a lower initial dose of amlodipine may be required.           Atorvastatin: Plasma concentrations of atorvastatin are higher (approximately 40% for Cmax and 30% for AUC) in healthy elderly subjects (age ≥65 years) than in young adults. Clinical data suggest a greater degree of LDL-lowering at any dose of atorvastatin in the elderly population compared to younger adults [see Use in Specific Populations (8.5)].             Pediatric           Amlodipine: Sixty-two hypertensive patients aged 6 to 17 years received doses of amlodipine between 1.25 mg and 20 mg. Weight-adjusted clearance and volume of distribution were similar to values in adults.           Atorvastatin: Pharmacokinetic data in the pediatric population are not available.             Gender          Atorvastatin: Plasma concentrations of atorvastatin in women differ from those in men (approximately 20% higher for Cmax and 10% lower for AUC); however, there is no clinically significant difference in LDL-C reduction with atorvastatin between men and women.             Renal Impairment          Amlodipine: The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. Patients with renal failure may therefore receive the usual initial amlodipine dose.           Atorvastatin: Renal disease has no influence on the plasma concentrations or LDL-C reduction of atorvastatin; thus, dose adjustment of atorvastatin in patients with renal dysfunction is not necessary [see Dosage and Administration (2) and Warnings and Precautions (5.1)].             Hemodialysis  While studies have not been conducted in patients with end-stage renal disease, hemodialysis is not expected to clear atorvastatin or amlodipine since both drugs are extensively bound to plasma proteins.           Hepatic Impairment           Amlodipine: Elderly patients and patients with hepatic insufficiency have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40–60%.           Atorvastatin: In patients with chronic alcoholic liver disease, plasma concentrations of atorvastatin are markedly increased. Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease. Cmax and AUC of atorvastatin are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease [see Contraindications (4.1)]. Atorvastatin is contraindicated in patients with active liver disease.             Heart Failure          Amlodipine: In patients with moderate to severe heart failure, the increase in AUC for amlodipine was similar to that seen in the elderly and in patients with hepatic insufficiency.               Effects of Other Drugs on CADUET          Amlodipine: No significant interactions are known.           Atorvastatin: Table 5 shows effects of other drugs on the pharmacokinetics of atorvastatin.  Table 5. Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin       Co-administered drug anddosing regimen Atorvastatin    Dose (mg) Change in AUC Change in Cmax      See  Warnings and Precautions (5.1) and  Drug Interactions (7) for clinical significance.Cyclosporine 5.2 mg/kg/day, stable dose 10 mg QD for 28 days ↑ 870% ↑1070%    Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days 10 mg, SD ↑ 940% ↑ 860%    Telaprevir 750 mg q8h, 10 days 20 mg, SD ↑ 790% ↑ 1060%     , The dose of saquinavir plus ritonavir in this study is not the clinically used dose. The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore, use the lowest dose necessary. Saquinavir 400 mg BID/ritonavir 400mg BID, 15 days 40 mg QD for 4 days ↑ 390% ↑ 430%    Clarithromycin 500 mg BID, 9 days 80 mg QD for 8 days ↑ 440% ↑ 540%    Darunavir 300 mg BID/ritonavir 100 mg BID, 9 days 10 mg QD for 4 days ↑ 340% ↑ 230%    Itraconazole 200 mg QD, 4 days 40 mg SD ↑ 330% ↑ 20%     Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days 10 mg QD for 4 days ↑ 250% ↑ 280%    Fosamprenavir 1400 mg BID, 14 days 10 mg QD for 4 days ↑ 230% ↑ 400%    Nelfinavir 1250 mg BID, 14 days 10 mg QD for 28 days ↑ 74% ↑ 220%    Grapefruit Juice, 240 mL QDGreater increases in AUC (up to 2.5-fold) and/or Cmax (up to 71%) have been reported with excessive grapefruit consumption (≥ 750 mL – 1.2 liters per day).  40 mg, SD ↑ 37% ↑ 16%   Diltiazem 240 mg QD, 28 days 40 mg, SD ↑ 51% No change   Erythromycin 500 mg QID, 7 days 10 mg, SD ↑ 33% ↑ 38%   Amlodipine 10 mg, single dose 80 mg, SD ↑ 15% ↓ 12 %   Cimetidine 300 mg QID, 2 weeks 10 mg QD for 2 weeks ↓ Less than 1% ↓ 11%   Colestipol 10 mg BID, 28 weeks 40 mg QD for 28 weeks Not determined ↓ 26%Single sample taken 8–16 h post dose.    Maalox TC® 30 mL QD, 17 days 10 mg QD for 15 days ↓ 33% ↓ 34%   Efavirenz 600 mg QD, 14 days 10 mg for 3 days ↓ 41% ↓ 1%    Rifampin 600 mg QD, 7 days (co-administered)Because of the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.  40 mg SD ↑ 30% ↑ 2.7-fold    Rifampin 600 mg QD, 5 days (doses separated)  40 mg SD ↓ 80% ↓ 40%    Gemfibrozil 600 mg BID, 7 days 40mg SD  ↑ 35% ↓ Less than 1%    Fenofibrate 160 mg QD, 7 days 40mg SD  ↑ 3% ↑ 2%   Boceprevir 800 mg TID, 7 days 40 mg SD  ↑2.30 fold ↑2.66 fold                Effects of CADUET on Other Drugs          Amlodipine: No significant interactions are known.           Atorvastatin: Table 6 shows the effects of atorvastatin on the pharmacokinetics of other drugs.  Table 6. Effect of Atorvastatin on the Pharmacokinetics of Co-administered Drugs       Atorvastatin Co-administered drug and dosing regimen    Drug/Dose (mg) Change in AUC Change in Cmax     80 mg QD for 15 days Antipyrine, 600 mg SD ↑ 3% ↓ 11%   80 mg QD for 14 days Digoxin 0.25 mg QD, 20 days ↑ 15% ↑ 20 %   40 mg QD for 22 days Oral contraceptive QD, 2 months      – norethindrone 1mg ↑ 28% ↑ 23%    – ethinyl estradiol 35 µg ↑ 19% ↑ 30%   10 mg, SD Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days No change No change   10 mg QD for 4 days Fosamprenavir 1400 mg BID, 14 days ↓ 27% ↓ 18%   10 mg QD for 4 days Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days No change No change</Section>
</Text><Sentences>
<Sentence id="1829" LabelDrug="Caduet" section="34070-3">
<SentenceText>Active Liver Disease, Which May Include Unexplained Persistent Elevations in Hepatic Transaminase Levels Pregnancy Lactation Active liver disease (4) Pregnancy (4) Lactation (4)</SentenceText>
</Sentence>
<Sentence id="1830" LabelDrug="Caduet" section="34068-7">
<SentenceText>Usual starting dose(mg daily) Maximum dose(mg daily) Amlodipine 5Start small adults or children, fragile, or elderly patients, or patients with hepatic insufficiency on 2.5 mg once daily (2) 10 Atorvastatin 10–20Start patients requiring large LDL-C reduction (&gt; 45%) at 40 mg once daily (2) 80 CADUET Dosage of CADUET must be individualized on the basis of both effectiveness and tolerance for each individual component in the treatment of hypertension/angina and hyperlipidemia.</SentenceText>
</Sentence>
<Sentence id="1831" LabelDrug="Caduet" section="34068-7">
<SentenceText>Select doses of amlodipine and atorvastatin independently.</SentenceText>
</Sentence>
<Sentence id="1832" LabelDrug="Caduet" section="34068-7">
<SentenceText>CADUET may be substituted for its individually titrated components.</SentenceText>
</Sentence>
<Sentence id="1833" LabelDrug="Caduet" section="34068-7">
<SentenceText>Patients may be given the equivalent dose of CADUET or a dose of CADUET with increased amounts of amlodipine, atorvastatin, or both for additional antianginal effects, blood pressure lowering, or lipid-lowering effect.</SentenceText>
</Sentence>
<Sentence id="1834" LabelDrug="Caduet" section="34068-7">
<SentenceText>CADUET may be used to provide additional therapy for patients already on one of its components.</SentenceText>
</Sentence>
<Sentence id="1835" LabelDrug="Caduet" section="34068-7">
<SentenceText>CADUET may be used to initiate treatment in patients with hyperlipidemia and either hypertension or angina.</SentenceText>
</Sentence>
<Sentence id="1836" LabelDrug="Caduet" section="34068-7">
<SentenceText>Amlodipine The usual initial antihypertensive oral dose of amlodipine is 5 mg once daily, and the maximum dose is 10 mg once daily.</SentenceText>
</Sentence>
<Sentence id="1837" LabelDrug="Caduet" section="34068-7">
<SentenceText>Pediatric (age &gt; 6 years), small adult, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding amlodipine to other antihypertensive therapy.</SentenceText>
</Sentence>
<Sentence id="1838" LabelDrug="Caduet" section="34068-7">
<SentenceText>Adjust dosage according to blood pressure goals.</SentenceText>
</Sentence>
<Sentence id="1839" LabelDrug="Caduet" section="34068-7">
<SentenceText>In general, wait 7 to 14 days between titration steps.</SentenceText>
</Sentence>
<Sentence id="1840" LabelDrug="Caduet" section="34068-7">
<SentenceText>Titration may proceed more rapidly, however, if clinically warranted, provided the patient is assessed frequently.</SentenceText>
</Sentence>
<Sentence id="1841" LabelDrug="Caduet" section="34068-7">
<SentenceText>Angina: The recommended dose of amlodipine for chronic stable or vasospastic angina is 5–10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency.</SentenceText>
</Sentence>
<Sentence id="1842" LabelDrug="Caduet" section="34068-7">
<SentenceText>Most patients will require 10 mg for adequate effect.</SentenceText>
</Sentence>
<Sentence id="1843" LabelDrug="Caduet" section="34068-7">
<SentenceText>Coronary Artery Disease: The recommended dose range of amlodipine for patients with CAD is 5–10 mg once daily.</SentenceText>
</Sentence>
<Sentence id="1844" LabelDrug="Caduet" section="34068-7">
<SentenceText>In clinical studies, the majority of patients required 10 mg.</SentenceText>
</Sentence>
<Sentence id="1845" LabelDrug="Caduet" section="34068-7">
<SentenceText>Pediatrics: The effective antihypertensive oral dose of amlodipine in pediatric patients ages 6–17 years is 2.5 mg to 5 mg once daily.</SentenceText>
</Sentence>
<Sentence id="1846" LabelDrug="Caduet" section="34068-7">
<SentenceText>Doses in excess of 5 mg daily have not been studied in pediatric patients.</SentenceText>
</Sentence>
<Sentence id="1847" LabelDrug="Caduet" section="34068-7">
<SentenceText>Atorvastatin (Hyperlipidemia) Hyperlipidemia and Mixed Dyslipidemia: The recommended starting dose of atorvastatin is 10 or 20 mg once daily.</SentenceText>
</Sentence>
<Sentence id="1848" LabelDrug="Caduet" section="34068-7">
<SentenceText>Patients who require a large reduction in LDL-C (more than 45%) may be started at 40 mg once daily.</SentenceText>
</Sentence>
<Sentence id="1849" LabelDrug="Caduet" section="34068-7">
<SentenceText>The dosage range of atorvastatin is 10 to 80 mg once daily.</SentenceText>
</Sentence>
<Sentence id="1850" LabelDrug="Caduet" section="34068-7">
<SentenceText>Atorvastatin can be administered as a single dose at any time of the day, with or without food.</SentenceText>
</Sentence>
<Sentence id="1851" LabelDrug="Caduet" section="34068-7">
<SentenceText>The starting dose and maintenance doses of atorvastatin should be individualized according to patient characteristics such as goal of therapy and response.</SentenceText>
</Sentence>
<Sentence id="1852" LabelDrug="Caduet" section="34068-7">
<SentenceText>After initiation and/or upon titration of atorvastatin, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.</SentenceText>
</Sentence>
<Sentence id="1853" LabelDrug="Caduet" section="34068-7">
<SentenceText>Homozygous Familial Hypercholesterolemia: The dosage range of atorvastatin in patients with HoFH is 10 to 80 mg daily.</SentenceText>
</Sentence>
<Sentence id="1854" LabelDrug="Caduet" section="34068-7">
<SentenceText>Atorvastatin should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.</SentenceText>
</Sentence>
<Sentence id="1855" LabelDrug="Caduet" section="34068-7">
<SentenceText>Concomitant Lipid-Lowering Therapy: Atorvastatin may be used with bile acid resins.</SentenceText>
</Sentence>
<Sentence id="1856" LabelDrug="Caduet" section="34068-7">
<SentenceText>Monitor for signs of myopathy in patients receiving the combination of HMG-CoA reductase inhibitors (statins) and fibrates.</SentenceText>
<Mention id="M1" type="Trigger" span="0 17" str="Monitor for signs"/>
<Mention id="M2" type="Precipitant" span="114 8" str="fibrates" code="6848ST447Q"/>
<Mention id="M3" type="SpecificInteraction" span="21 8" str="myopathy" code="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<Interaction id="I1" type="Pharmacodynamic interaction" trigger="M1" precipitant="M2" effect="M3"/>
</Sentence>
<Sentence id="1857" LabelDrug="Caduet" section="34068-7">
<SentenceText>Patients with Renal Impairment: Renal disease does not affect the plasma concentrations nor LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary.</SentenceText>
</Sentence>
<Sentence id="1858" LabelDrug="Caduet" section="34068-7">
<SentenceText>Use with Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors: In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the hepatitis C protease inhibitor (telaprevir), avoid therapy with atorvastatin.</SentenceText>
<Mention id="M18" type="Trigger" span="228 13" str="avoid therapy"/>
<Mention id="M5" type="Precipitant" span="23 14" str="Clarithromycin" code="H1250JIK0A"/>
<Mention id="M7" type="Precipitant" span="104 12" str="cyclosporine" code="83HN0GTJ6D"/>
<Mention id="M9" type="Precipitant" span="183 30" str="hepatitis C protease inhibitor" code="N0000182639"/>
<Mention id="M11" type="Precipitant" span="124 23" str="HIV protease inhibitors" code="N0000000246"/>
<Mention id="M13" type="Precipitant" span="39 12" str="Itraconazole" code="304NUG5GF4"/>
<Mention id="M15" type="Precipitant" span="64 19" str="Protease Inhibitors" code="N0000175889"/>
<Mention id="M17" type="Precipitant" span="215 10" str="telaprevir" code="655M5O3W0U"/>
<Mention id="M19" type="Precipitant" span="149 25" str="tipranavir plus ritonavir" code="NO MAP"/>
<Interaction id="I2" type="Unspecified interaction" trigger="M18" precipitant="M5"/>
<Interaction id="I3" type="Unspecified interaction" trigger="M18" precipitant="M7"/>
<Interaction id="I4" type="Unspecified interaction" trigger="M18" precipitant="M9"/>
<Interaction id="I5" type="Unspecified interaction" trigger="M18" precipitant="M11"/>
<Interaction id="I6" type="Unspecified interaction" trigger="M18" precipitant="M13"/>
<Interaction id="I7" type="Unspecified interaction" trigger="M18" precipitant="M15"/>
<Interaction id="I8" type="Unspecified interaction" trigger="M18" precipitant="M17"/>
<Interaction id="I9" type="Unspecified interaction" trigger="M18" precipitant="M19"/>
</Sentence>
<Sentence id="1859" LabelDrug="Caduet" section="34068-7">
<SentenceText>In patients with HIV taking lopinavir plus ritonavir, use the lowest necessary dose of atorvastatin.</SentenceText>
<Mention id="M20" type="Trigger" span="54 29" str="use the lowest necessary dose"/>
<Mention id="M21" type="Precipitant" span="28 24" str="lopinavir plus ritonavir" code="NO MAP"/>
<Interaction id="I10" type="Pharmacokinetic interaction" trigger="M20" precipitant="M21" effect="C54355"/>
</Sentence>
<Sentence id="1860" LabelDrug="Caduet" section="34068-7">
<SentenceText>In patients taking clarithromycin, itraconazole, or in patients with HIV taking a combination of saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, limit therapy with atorvastatin to 20 mg, and make appropriate clinical assessment to ensure that the lowest dose necessary of atorvastatin is employed.</SentenceText>
<Mention id="M32" type="Trigger" span="300 21" str="lowest dose necessary"/>
<Mention id="M23" type="Precipitant" span="19 14" str="clarithromycin" code="H1250JIK0A"/>
<Mention id="M25" type="Precipitant" span="124 24" str="darunavir plus ritonavir" code="NO MAP"/>
<Mention id="M27" type="Precipitant" span="150 13" str="fosamprenavir" code="WOU1621EEG"/>
<Mention id="M29" type="Precipitant" span="168 28" str="fosamprenavir plus ritonavir" code="NO MAP"/>
<Mention id="M31" type="Precipitant" span="35 12" str="itraconazole" code="304NUG5GF4"/>
<Mention id="M33" type="Precipitant" span="97 25" str="saquinavir plus ritonavir" code="NO MAP"/>
<Interaction id="I11" type="Pharmacokinetic interaction" trigger="M32" precipitant="M23" effect="C54355"/>
<Interaction id="I12" type="Pharmacokinetic interaction" trigger="M32" precipitant="M25" effect="C54355"/>
<Interaction id="I13" type="Pharmacokinetic interaction" trigger="M32" precipitant="M27" effect="C54355"/>
<Interaction id="I14" type="Pharmacokinetic interaction" trigger="M32" precipitant="M29" effect="C54355"/>
<Interaction id="I15" type="Pharmacokinetic interaction" trigger="M32" precipitant="M31" effect="C54355"/>
<Interaction id="I16" type="Pharmacokinetic interaction" trigger="M32" precipitant="M33" effect="C54355"/>
</Sentence>
<Sentence id="1861" LabelDrug="Caduet" section="34068-7">
<SentenceText>In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, limit therapy with atorvastatin to 40 mg, and make appropriate clinical assessment to ensure that the lowest dose necessary of atorvastatin is employed.</SentenceText>
<Mention id="M40" type="Trigger" span="209 21" str="lowest dose necessary"/>
<Mention id="M35" type="Precipitant" span="95 10" str="boceprevir" code="89BT58KELH"/>
<Mention id="M37" type="Precipitant" span="64 30" str="hepatitis C protease inhibitor" code="N0000182639"/>
<Mention id="M39" type="Precipitant" span="23 22" str="HIV protease inhibitor" code="N0000000246"/>
<Mention id="M41" type="Precipitant" span="46 10" str="nelfinavir" code="HO3OGH5D7I"/>
<Interaction id="I17" type="Pharmacokinetic interaction" trigger="M40" precipitant="M35" effect="C54355"/>
<Interaction id="I18" type="Pharmacokinetic interaction" trigger="M40" precipitant="M37" effect="C54355"/>
<Interaction id="I19" type="Pharmacokinetic interaction" trigger="M40" precipitant="M39" effect="C54355"/>
<Interaction id="I20" type="Pharmacokinetic interaction" trigger="M40" precipitant="M41" effect="C54355"/>
</Sentence>
<Sentence id="1862" LabelDrug="Caduet" section="34068-7">
<SentenceText>Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10 Years to 17 Years of Age): The recommended starting dose of atorvastatin is 10 mg/day; the usual dose range is 10 to 20 mg orally once daily.</SentenceText>
</Sentence>
<Sentence id="1863" LabelDrug="Caduet" section="34068-7">
<SentenceText>Doses should be individualized according to the recommended goal of therapy.</SentenceText>
</Sentence>
<Sentence id="1864" LabelDrug="Caduet" section="34068-7">
<SentenceText>Adjustments should be made at intervals of 4 weeks or more.</SentenceText>
</Sentence>
<Sentence id="1865" LabelDrug="Caduet" section="34073-7">
<SentenceText>Data from a drug-drug interaction study involving 10 mg of amlodipine and 80 mg of atorvastatin in healthy subjects indicate that the pharmacokinetics of amlodipine are not altered when the drugs are co-administered.</SentenceText>
</Sentence>
<Sentence id="1866" LabelDrug="Caduet" section="34073-7">
<SentenceText>The effect of amlodipine on the pharmacokinetics of atorvastatin showed no effect on the Cmax: 91% (90% confidence interval: 80 to 103%), but the AUC of atorvastatin increased by 18% (90% confidence interval: 109 to 127%) in the presence of amlodipine, which is not clinically meaningful.</SentenceText>
</Sentence>
<Sentence id="1867" LabelDrug="Caduet" section="34073-7">
<SentenceText>No drug interaction studies have been conducted with CADUET and other drugs, although studies have been conducted in the individual amlodipine and atorvastatin components, as described below: Increased Risk of Myopathy/Rhabdomyolysis (2, 5.1, 7, 12.3) Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir) Avoid atorvastatin Lopinavir plus ritonavir Use lowest dose necessary Clarithromycin, itraconazole,HIV protease inhibitors (saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir) Do not exceed 20 mg atorvastatin daily HIV protease inhibitor (nelfinavir) Hepatitis C protease inhibitor (boceprevir) Do not exceed 40 mg atorvastatin daily Other Lipid-Lowering Medications: Increased risk of myopathy (7).</SentenceText>
<Mention id="M57" type="Trigger" span="192 14" str="Increased Risk"/>
<Mention id="M43" type="Precipitant" span="252 12" str="Cyclosporine" code="83HN0GTJ6D"/>
<Mention id="M59" type="SpecificInteraction" span="210 23" str="Myopathy/Rhabdomyolysis" code="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<Mention id="M46" type="Precipitant" span="319 30" str="hepatitis C protease inhibitor" code="N0000182639"/>
<Mention id="M75" type="Precipitant" span="266 23" str="HIV protease inhibitors" code="N0000000246"/>
<Mention id="M51" type="Trigger" span="777 14" str="Increased risk"/>
<Mention id="M79" type="Precipitant" span="749 26" str="Lipid-Lowering Medications" code="NO MAP"/>
<Mention id="M53" type="SpecificInteraction" span="795 8" str="myopathy" code="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<Mention id="M55" type="Precipitant" span="351 10" str="telaprevir" code="655M5O3W0U"/>
<Mention id="M58" type="Precipitant" span="291 25" str="tipranavir plus ritonavir" code="NO MAP"/>
<Mention id="M80" type="Trigger" span="585 13" str="Do not exceed"/>
<Mention id="M61" type="Precipitant" span="692 10" str="boceprevir" code="89BT58KELH"/>
<Mention id="M82" type="Trigger" span="407 25" str="Use lowest dose necessary"/>
<Mention id="M63" type="Precipitant" span="433 14" str="Clarithromycin" code="H1250JIK0A"/>
<Mention id="M65" type="Precipitant" span="514 24" str="darunavir plus ritonavir" code="NO MAP"/>
<Mention id="M67" type="Precipitant" span="540 13" str="fosamprenavir" code="WOU1621EEG"/>
<Mention id="M69" type="Precipitant" span="555 28" str="fosamprenavir plus ritonavir" code="NO MAP"/>
<Mention id="M71" type="Precipitant" span="660 30" str="Hepatitis C protease inhibitor" code="N0000182639"/>
<Mention id="M73" type="Precipitant" span="266 22" str="HIV protease inhibitor" code="N0000000246"/>
<Mention id="M77" type="Precipitant" span="449 12" str="itraconazole" code="304NUG5GF4"/>
<Mention id="M81" type="Precipitant" span="648 10" str="nelfinavir" code="HO3OGH5D7I"/>
<Mention id="M83" type="Precipitant" span="487 25" str="saquinavir plus ritonavir" code="NO MAP"/>
<Mention id="M84" type="Trigger" span="363 5" str="Avoid"/>
<Mention id="M85" type="Precipitant" span="382 24" str="Lopinavir plus ritonavir" code="NO MAP"/>
<Interaction id="I21" type="Pharmacodynamic interaction" trigger="M57" precipitant="M43" effect="M59"/>
<Interaction id="I22" type="Pharmacodynamic interaction" trigger="M57" precipitant="M46" effect="M59"/>
<Interaction id="I23" type="Pharmacodynamic interaction" trigger="M57" precipitant="M75" effect="M59"/>
<Interaction id="I24" type="Pharmacodynamic interaction" trigger="M51" precipitant="M79" effect="M53"/>
<Interaction id="I25" type="Pharmacodynamic interaction" trigger="M57" precipitant="M55" effect="M59"/>
<Interaction id="I26" type="Pharmacodynamic interaction" trigger="M57" precipitant="M58" effect="M59"/>
<Interaction id="I27" type="Pharmacokinetic interaction" trigger="M80" precipitant="M61" effect="C54355"/>
<Interaction id="I28" type="Pharmacokinetic interaction" trigger="M82" precipitant="M63" effect="C54355"/>
<Interaction id="I29" type="Pharmacokinetic interaction" trigger="M82" precipitant="M65" effect="C54355"/>
<Interaction id="I30" type="Pharmacokinetic interaction" trigger="M82" precipitant="M67" effect="C54355"/>
<Interaction id="I31" type="Pharmacokinetic interaction" trigger="M82" precipitant="M69" effect="C54355"/>
<Interaction id="I32" type="Pharmacokinetic interaction" trigger="M80" precipitant="M71" effect="C54355"/>
<Interaction id="I33" type="Pharmacokinetic interaction" trigger="M80" precipitant="M73" effect="C54355"/>
<Interaction id="I34" type="Pharmacokinetic interaction" trigger="M82" precipitant="M75" effect="C54355"/>
<Interaction id="I35" type="Pharmacokinetic interaction" trigger="M82" precipitant="M77" effect="C54355"/>
<Interaction id="I36" type="Pharmacokinetic interaction" trigger="M80" precipitant="M79" effect="C54355"/>
<Interaction id="I37" type="Pharmacokinetic interaction" trigger="M80" precipitant="M81" effect="C54355"/>
<Interaction id="I38" type="Pharmacokinetic interaction" trigger="M82" precipitant="M83" effect="C54355"/>
<Interaction id="I39" type="Unspecified interaction" trigger="M84" precipitant="M85"/>
</Sentence>
<Sentence id="1868" LabelDrug="Caduet" section="34073-7">
<SentenceText>Rifampin: Take at same time as CADUET (7.9).</SentenceText>
</Sentence>
<Sentence id="1869" LabelDrug="Caduet" section="34073-7">
<SentenceText>Oral Contraceptives: Norethindrone and ethinyl estradiol may be increased (7.11).</SentenceText>
<Mention id="M90" type="Trigger" span="64 9" str="increased"/>
<Mention id="M87" type="Precipitant" span="39 17" str="ethinyl estradiol" code="423D2T571U"/>
<Mention id="M89" type="Precipitant" span="21 13" str="Norethindrone" code="T18F433X4S"/>
<Mention id="M91" type="Precipitant" span="0 19" str="Oral Contraceptives" code="NO MAP"/>
<Interaction id="I40" type="Pharmacokinetic interaction" trigger="M90" precipitant="M87" effect="C54357"/>
<Interaction id="I41" type="Pharmacokinetic interaction" trigger="M90" precipitant="M89" effect="C54357"/>
<Interaction id="I42" type="Pharmacokinetic interaction" trigger="M90" precipitant="M91" effect="C54357"/>
</Sentence>
<Sentence id="1870" LabelDrug="Caduet" section="34073-7">
<SentenceText>Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction.</SentenceText>
<Mention id="M92" type="Trigger" span="101 27" str="increased systemic exposure "/>
<Mention id="M93" type="Trigger" span="159 14" str=" dose reduction"/>
<Mention id="M94" type="Precipitant" span="51 16" str="CYP3A inhibitors" code="N0000191001"/>
<Interaction id="I43" type="Pharmacokinetic interaction" trigger="M92;M93" precipitant="M94" effect="C54355"/>
</Sentence>
<Sentence id="1871" LabelDrug="Caduet" section="34073-7">
<SentenceText>Monitor for symptoms of hypotension and edema when amlodipine is co-administered with CYP3A inhibitors to determine the need for dose adjustment.</SentenceText>
<Mention id="M98" type="Trigger" span="0 20" str="Monitor for symptoms"/>
<Mention id="M99" type="Precipitant" span="86 16" str="CYP3A inhibitors" code="N0000191001"/>
<Mention id="M97" type="SpecificInteraction" span="40 5" str="edema" code="267038008: Edema (finding)"/>
<Mention id="M100" type="SpecificInteraction" span="24 11" str="hypotension" code="45007003: Low blood pressure (disorder)"/>
<Interaction id="I44" type="Pharmacodynamic interaction" trigger="M98" precipitant="M99" effect="M97"/>
<Interaction id="I45" type="Pharmacodynamic interaction" trigger="M98" precipitant="M99" effect="M100"/>
</Sentence>
<Sentence id="1872" LabelDrug="Caduet" section="34073-7">
<SentenceText>CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine.</SentenceText>
</Sentence>
<Sentence id="1873" LabelDrug="Caduet" section="34073-7">
<SentenceText>Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers.</SentenceText>
<Mention id="M101" type="Trigger" span="15 27" str="should be closely monitored"/>
<Mention id="M102" type="Precipitant" span="83 14" str="CYP3A inducers" code="N0000190118"/>
<Mention id="M103" type="SpecificInteraction" span="0 14" str="Blood pressure" code="38936003: Abnormal blood pressure (finding)"/>
<Interaction id="I46" type="Pharmacodynamic interaction" trigger="M101" precipitant="M102" effect="M103"/>
</Sentence>
<Sentence id="1874" LabelDrug="Caduet" section="34073-7">
<SentenceText>Sildenafil Monitor for hypotension when sildenafil is co-administered with amlodipine.</SentenceText>
<Mention id="M104" type="Trigger" span="11 7" str="Monitor"/>
<Mention id="M105" type="Precipitant" span="40 10" str="sildenafil" code="3M7OB98Y7H"/>
<Mention id="M106" type="SpecificInteraction" span="23 11" str="hypotension" code="45007003: Low blood pressure (disorder)"/>
<Interaction id="I47" type="Pharmacodynamic interaction" trigger="M104" precipitant="M105" effect="M106"/>
</Sentence>
<Sentence id="1875" LabelDrug="Caduet" section="34073-7">
<SentenceText>Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered.</SentenceText>
<Mention id="M109" type="Trigger" span="34 30" str="increase the systemic exposure"/>
<Mention id="M108" type="Precipitant" span="68 12" str="cyclosporine" code="83HN0GTJ6D"/>
<Mention id="M110" type="Precipitant" span="84 10" str="tacrolimus" code="WM0HAQ4WNM"/>
<Interaction id="I48" type="Pharmacokinetic interaction" trigger="M109" precipitant="M108" effect="C54357"/>
<Interaction id="I49" type="Pharmacokinetic interaction" trigger="M109" precipitant="M110" effect="C54357"/>
</Sentence>
<Sentence id="1876" LabelDrug="Caduet" section="34073-7">
<SentenceText>Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended and adjust the dose when appropriate.</SentenceText>
<Mention id="M114" type="Trigger" span="0 19" str="Frequent monitoring"/>
<Mention id="M112" type="Precipitant" span="46 12" str="cyclosporine" code="83HN0GTJ6D"/>
<Mention id="M116" type="SpecificInteraction" span="23 19" str="trough blood levels" code="NO MAP"/>
<Mention id="M115" type="Precipitant" span="63 10" str="tacrolimus" code="WM0HAQ4WNM"/>
<Interaction id="I50" type="Pharmacodynamic interaction" trigger="M114" precipitant="M112" effect="M116"/>
<Interaction id="I51" type="Pharmacodynamic interaction" trigger="M114" precipitant="M115" effect="M116"/>
</Sentence>
<Sentence id="1877" LabelDrug="Caduet" section="34073-7">
<SentenceText>Atorvastatin The risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole).</SentenceText>
<Mention id="M135" type="Trigger" span="17 4;67 9" str="risk | increased"/>
<Mention id="M118" type="Precipitant" span="218 14" str="clarithromycin" code="H1250JIK0A"/>
<Mention id="M137" type="SpecificInteraction" span="25 8" str="myopathy" code="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<Mention id="M121" type="Precipitant" span="169 12" str="cyclosporine" code="83HN0GTJ6D"/>
<Mention id="M124" type="Precipitant" span="111 23" str="fibric acid derivatives" code="6848ST447Q"/>
<Mention id="M127" type="Precipitant" span="234 23" str="HIV protease inhibitors" code="N0000000246"/>
<Mention id="M130" type="Precipitant" span="263 12" str="itraconazole" code="304NUG5GF4"/>
<Mention id="M133" type="Precipitant" span="136 31" str="lipid-modifying doses of niacin" code="2679MF687A"/>
<Mention id="M136" type="Precipitant" span="186 24" str="strong CYP3A4 inhibitors" code="N0000182141"/>
<Interaction id="I52" type="Pharmacodynamic interaction" trigger="M135" precipitant="M118" effect="M137"/>
<Interaction id="I53" type="Pharmacodynamic interaction" trigger="M135" precipitant="M121" effect="M137"/>
<Interaction id="I54" type="Pharmacodynamic interaction" trigger="M135" precipitant="M124" effect="M137"/>
<Interaction id="I55" type="Pharmacodynamic interaction" trigger="M135" precipitant="M127" effect="M137"/>
<Interaction id="I56" type="Pharmacodynamic interaction" trigger="M135" precipitant="M130" effect="M137"/>
<Interaction id="I57" type="Pharmacodynamic interaction" trigger="M135" precipitant="M133" effect="M137"/>
<Interaction id="I58" type="Pharmacodynamic interaction" trigger="M135" precipitant="M136" effect="M137"/>
</Sentence>
<Sentence id="1878" LabelDrug="Caduet" section="34073-7">
<SentenceText>Concomitant administration of atorvastatin with strong inhibitors of CYP3A4 can lead to increases in plasma concentrations of atorvastatin.</SentenceText>
<Mention id="M138" type="Trigger" span="88 34" str="increases in plasma concentrations"/>
<Mention id="M139" type="Precipitant" span="48 27" str="strong inhibitors of CYP3A4" code="N0000182141"/>
<Interaction id="I59" type="Pharmacokinetic interaction" trigger="M138" precipitant="M139" effect="C54355"/>
</Sentence>
<Sentence id="1879" LabelDrug="Caduet" section="34073-7">
<SentenceText>The extent of interaction and potentiation of effects depend on the variability of effect on CYP3A4.</SentenceText>
</Sentence>
<Sentence id="1880" LabelDrug="Caduet" section="34073-7">
<SentenceText>Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 80 mg with clarithromycin (500 mg twice daily) compared to that of atorvastatin alone.</SentenceText>
<Mention id="M140" type="Trigger" span="29 3;51 9" str="AUC | increased"/>
<Mention id="M141" type="Precipitant" span="120 14" str="clarithromycin" code="H1250JIK0A"/>
<Interaction id="I60" type="Pharmacokinetic interaction" trigger="M140" precipitant="M141" effect="C54605"/>
</Sentence>
<Sentence id="1881" LabelDrug="Caduet" section="34073-7">
<SentenceText>Therefore, in patients taking clarithromycin, avoid atorvastatin doses &gt;20 mg.</SentenceText>
<Mention id="M142" type="Trigger" span="46 5;65 7" str="avoid | doses &gt;"/>
<Mention id="M143" type="Precipitant" span="30 14" str="clarithromycin" code="H1250JIK0A"/>
<Interaction id="I61" type="Pharmacokinetic interaction" trigger="M142" precipitant="M143" effect="C54355"/>
</Sentence>
<Sentence id="1882" LabelDrug="Caduet" section="34073-7">
<SentenceText>Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin with several combinations of HIV protease inhibitors, as well as with the hepatitis C protease inhibitor telaprevir, compared to that of atorvastatin alone.</SentenceText>
<Mention id="M150" type="Trigger" span="49 3;71 9" str="AUC | increased"/>
<Mention id="M145" type="Precipitant" span="142 39" str="combinations of HIV protease inhibitors" code="N0000000246"/>
<Mention id="M147" type="Precipitant" span="203 30" str="hepatitis C protease inhibitor" code="N0000182639"/>
<Mention id="M149" type="Precipitant" span="203 41" str="hepatitis C protease inhibitor telaprevir" code="655M5O3W0U"/>
<Mention id="M151" type="Precipitant" span="234 10" str="telaprevir" code="655M5O3W0U"/>
<Interaction id="I62" type="Pharmacokinetic interaction" trigger="M150" precipitant="M145" effect="C54605"/>
<Interaction id="I63" type="Pharmacokinetic interaction" trigger="M150" precipitant="M147" effect="C54605"/>
<Interaction id="I64" type="Pharmacokinetic interaction" trigger="M150" precipitant="M149" effect="C54605"/>
<Interaction id="I65" type="Pharmacokinetic interaction" trigger="M150" precipitant="M151" effect="C54605"/>
</Sentence>
<Sentence id="1883" LabelDrug="Caduet" section="34073-7">
<SentenceText>Therefore, in patients taking the HIV protease inhibitor tipranavir plus ritonavir, or the hepatitis C protease inhibitor telaprevir, concomitant use of atorvastatin should be avoided.</SentenceText>
<Mention id="M162" type="Trigger" span="166 17" str="should be avoided"/>
<Mention id="M153" type="Precipitant" span="91 30" str="hepatitis C protease inhibitor" code="N0000182639"/>
<Mention id="M155" type="Precipitant" span="91 41" str="hepatitis C protease inhibitor telaprevir" code="655M5O3W0U"/>
<Mention id="M157" type="Precipitant" span="34 22" str="HIV protease inhibitor" code="N0000000246"/>
<Mention id="M159" type="Precipitant" span="34 48" str="HIV protease inhibitor tipranavir plus ritonavir" code="NO MAP"/>
<Mention id="M161" type="Precipitant" span="122 10" str="telaprevir" code="655M5O3W0U"/>
<Mention id="M163" type="Precipitant" span="57 25" str="tipranavir plus ritonavir" code="NO MAP"/>
<Interaction id="I66" type="Unspecified interaction" trigger="M162" precipitant="M153"/>
<Interaction id="I67" type="Unspecified interaction" trigger="M162" precipitant="M155"/>
<Interaction id="I68" type="Unspecified interaction" trigger="M162" precipitant="M157"/>
<Interaction id="I69" type="Unspecified interaction" trigger="M162" precipitant="M159"/>
<Interaction id="I70" type="Unspecified interaction" trigger="M162" precipitant="M161"/>
<Interaction id="I71" type="Unspecified interaction" trigger="M162" precipitant="M163"/>
</Sentence>
<Sentence id="1884" LabelDrug="Caduet" section="34073-7">
<SentenceText>In patients taking the HIV protease inhibitor lopinavir plus ritonavir, caution should be used when prescribing atorvastatin and the lowest dose necessary should be used.</SentenceText>
<Mention id="M168" type="Trigger" span="133 21" str="lowest dose necessary"/>
<Mention id="M165" type="Precipitant" span="23 22" str="HIV protease inhibitor" code="N0000000246"/>
<Mention id="M167" type="Precipitant" span="23 47" str="HIV protease inhibitor lopinavir plus ritonavir" code="NO MAP"/>
<Mention id="M169" type="Precipitant" span="46 24" str="lopinavir plus ritonavir" code="NO MAP"/>
<Interaction id="I72" type="Pharmacokinetic interaction" trigger="M168" precipitant="M165" effect="C54355"/>
<Interaction id="I73" type="Pharmacokinetic interaction" trigger="M168" precipitant="M167" effect="C54355"/>
<Interaction id="I74" type="Pharmacokinetic interaction" trigger="M168" precipitant="M169" effect="C54355"/>
</Sentence>
<Sentence id="1885" LabelDrug="Caduet" section="34073-7">
<SentenceText>In patients taking the HIV protease inhibitors saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, the dose of atorvastatin should not exceed 20 mg.</SentenceText>
<Mention id="M180" type="Trigger" span="152 4;173 17" str="dose | should not exceed"/>
<Mention id="M171" type="Precipitant" span="74 24" str="darunavir plus ritonavir" code="NO MAP"/>
<Mention id="M173" type="Precipitant" span="100 13" str="fosamprenavir" code="WOU1621EEG"/>
<Mention id="M175" type="Precipitant" span="118 28" str="fosamprenavir plus ritonavir" code="NO MAP"/>
<Mention id="M177" type="Precipitant" span="23 23" str="HIV protease inhibitors" code="N0000000246"/>
<Mention id="M179" type="Precipitant" span="23 49" str="HIV protease inhibitors saquinavir plus ritonavir" code="NO MAP"/>
<Mention id="M181" type="Precipitant" span="47 25" str="saquinavir plus ritonavir" code="NO MAP"/>
<Interaction id="I75" type="Pharmacokinetic interaction" trigger="M180" precipitant="M171" effect="C54355"/>
<Interaction id="I76" type="Pharmacokinetic interaction" trigger="M180" precipitant="M173" effect="C54355"/>
<Interaction id="I77" type="Pharmacokinetic interaction" trigger="M180" precipitant="M175" effect="C54355"/>
<Interaction id="I78" type="Pharmacokinetic interaction" trigger="M180" precipitant="M177" effect="C54355"/>
<Interaction id="I79" type="Pharmacokinetic interaction" trigger="M180" precipitant="M179" effect="C54355"/>
<Interaction id="I80" type="Pharmacokinetic interaction" trigger="M180" precipitant="M181" effect="C54355"/>
</Sentence>
<Sentence id="1886" LabelDrug="Caduet" section="34073-7">
<SentenceText>In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, the dose of atorvastatin should not exceed 40 mg and close clinical monitoring is recommended.</SentenceText>
<Mention id="M192" type="Trigger" span="111 4;132 17" str="dose | should not exceed"/>
<Mention id="M183" type="Precipitant" span="95 10" str="boceprevir" code="89BT58KELH"/>
<Mention id="M185" type="Precipitant" span="64 30" str="hepatitis C protease inhibitor" code="N0000182639"/>
<Mention id="M187" type="Precipitant" span="64 41" str="hepatitis C protease inhibitor boceprevir" code="89BT58KELH"/>
<Mention id="M189" type="Precipitant" span="23 22" str="HIV protease inhibitor" code="N0000000246"/>
<Mention id="M191" type="Precipitant" span="23 33" str="HIV protease inhibitor nelfinavir" code="HO3OGH5D7I"/>
<Mention id="M193" type="Precipitant" span="46 10" str="nelfinavir" code="HO3OGH5D7I"/>
<Interaction id="I81" type="Pharmacokinetic interaction" trigger="M192" precipitant="M183" effect="C54355"/>
<Interaction id="I82" type="Pharmacokinetic interaction" trigger="M192" precipitant="M185" effect="C54355"/>
<Interaction id="I83" type="Pharmacokinetic interaction" trigger="M192" precipitant="M187" effect="C54355"/>
<Interaction id="I84" type="Pharmacokinetic interaction" trigger="M192" precipitant="M189" effect="C54355"/>
<Interaction id="I85" type="Pharmacokinetic interaction" trigger="M192" precipitant="M191" effect="C54355"/>
<Interaction id="I86" type="Pharmacokinetic interaction" trigger="M192" precipitant="M193" effect="C54355"/>
</Sentence>
<Sentence id="1887" LabelDrug="Caduet" section="34073-7">
<SentenceText>Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 40 mg and itraconazole 200 mg.</SentenceText>
<Mention id="M194" type="Trigger" span="27 3;49 9" str="AUC | increased"/>
<Mention id="M195" type="Precipitant" span="117 12" str="itraconazole" code="304NUG5GF4"/>
<Interaction id="I87" type="Pharmacokinetic interaction" trigger="M194" precipitant="M195" effect="C54605"/>
</Sentence>
<Sentence id="1888" LabelDrug="Caduet" section="34073-7">
<SentenceText>Therefore, in patients taking itraconazole, avoid atorvastatin doses &gt;20 mg.</SentenceText>
<Mention id="M196" type="Trigger" span="44 5;63 7" str="avoid | doses &gt;"/>
<Mention id="M197" type="Precipitant" span="30 12" str="itraconazole" code="304NUG5GF4"/>
<Interaction id="I88" type="Pharmacokinetic interaction" trigger="M196" precipitant="M197" effect="C54355"/>
</Sentence>
<Sentence id="1889" LabelDrug="Caduet" section="34073-7">
<SentenceText>Contains one or more components that inhibit CYP3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (&gt; 1.2 liters per day).</SentenceText>
<Mention id="M200" type="Trigger" span="60 30" str="increase plasma concentrations"/>
<Mention id="M199" type="Precipitant" span="21 30" str="components that inhibit CYP3A4" code="N0000182141"/>
<Mention id="M201" type="Precipitant" span="124 26" str="excessive grapefruit juice" code="JQ9EK2H6BG"/>
<Interaction id="I89" type="Pharmacokinetic interaction" trigger="M200" precipitant="M199" effect="C54355"/>
<Interaction id="I90" type="Pharmacokinetic interaction" trigger="M200" precipitant="M201" effect="C54355"/>
</Sentence>
<Sentence id="1890" LabelDrug="Caduet" section="34073-7">
<SentenceText>Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter.</SentenceText>
</Sentence>
<Sentence id="1891" LabelDrug="Caduet" section="34073-7">
<SentenceText>Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin.</SentenceText>
<Mention id="M204" type="Trigger" span="51 28" str="increase the bioavailability"/>
<Mention id="M203" type="Precipitant" span="33 12" str="cyclosporine" code="83HN0GTJ6D"/>
<Mention id="M205" type="Precipitant" span="0 25" str="Inhibitors of the OATP1B1" code="NO MAP"/>
<Interaction id="I91" type="Pharmacokinetic interaction" trigger="M204" precipitant="M203" effect="C54355"/>
<Interaction id="I92" type="Pharmacokinetic interaction" trigger="M204" precipitant="M205" effect="C54355"/>
</Sentence>
<Sentence id="1892" LabelDrug="Caduet" section="34073-7">
<SentenceText>Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 10 mg and cyclosporine 5.2 mg/kg/day compared to that of atorvastatin alone.</SentenceText>
<Mention id="M206" type="Trigger" span="13 3;35 9" str="AUC | increased"/>
<Mention id="M207" type="Precipitant" span="103 12" str="cyclosporine" code="83HN0GTJ6D"/>
<Interaction id="I93" type="Pharmacokinetic interaction" trigger="M206" precipitant="M207" effect="C54605"/>
</Sentence>
<Sentence id="1893" LabelDrug="Caduet" section="34073-7">
<SentenceText>The co-administration of atorvastatin with cyclosporine should be avoided.</SentenceText>
<Mention id="M208" type="Trigger" span="56 17" str="should be avoided"/>
<Mention id="M209" type="Precipitant" span="43 12" str="cyclosporine" code="83HN0GTJ6D"/>
<Interaction id="I94" type="Unspecified interaction" trigger="M208" precipitant="M209"/>
</Sentence>
<Sentence id="1894" LabelDrug="Caduet" section="34073-7">
<SentenceText>Because of an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are co-administered with gemfibrozil, avoid concomitant administration of atorvastatin with gemfibrozil.</SentenceText>
<Mention id="M216" type="Trigger" span="14 14" str="increased risk"/>
<Mention id="M217" type="Precipitant" span="115 11" str="gemfibrozil" code="Q8X02027X3"/>
<Mention id="M212" type="SpecificInteraction" span="32 8" str="myopathy" code="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<Mention id="M215" type="SpecificInteraction" span="32 23" str="myopathy/rhabdomyolysis" code="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<Mention id="M218" type="SpecificInteraction" span="41 14" str="rhabdomyolysis" code="240131006: Rhabdomyolysis (disorder)"/>
<Interaction id="I95" type="Pharmacodynamic interaction" trigger="M216" precipitant="M217" effect="M212"/>
<Interaction id="I96" type="Pharmacodynamic interaction" trigger="M216" precipitant="M217" effect="M215"/>
<Interaction id="I97" type="Pharmacodynamic interaction" trigger="M216" precipitant="M217" effect="M218"/>
</Sentence>
<Sentence id="1895" LabelDrug="Caduet" section="34073-7">
<SentenceText>The risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates.</SentenceText>
<Mention id="M219" type="Trigger" span="4 4;75 9" str="risk | increased"/>
<Mention id="M220" type="Precipitant" span="125 8" str="fibrates" code="6848ST447Q"/>
<Mention id="M221" type="SpecificInteraction" span="12 8" str="myopathy" code="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<Interaction id="I98" type="Pharmacodynamic interaction" trigger="M219" precipitant="M220" effect="M221"/>
</Sentence>
<Sentence id="1896" LabelDrug="Caduet" section="34073-7">
<SentenceText>The risk of skeletal muscle effects may be enhanced when atorvastatin is used in combination with niacin; consider a reduction in atorvastatin dosage in this setting.</SentenceText>
<Mention id="M222" type="Trigger" span="4 4;43 8" str="risk | enhanced"/>
<Mention id="M226" type="Precipitant" span="98 6" str="niacin" code="2679MF687A"/>
<Mention id="M224" type="SpecificInteraction" span="12 23" str="skeletal muscle effects" code="75047002: Disorder of skeletal muscle (disorder)"/>
<Mention id="M225" type="Trigger" span="117 9;143 6" str="reduction | dosage"/>
<Interaction id="I99" type="Pharmacodynamic interaction" trigger="M222" precipitant="M226" effect="M224"/>
<Interaction id="I100" type="Pharmacokinetic interaction" trigger="M225" precipitant="M226" effect="C54355"/>
</Sentence>
<Sentence id="1897" LabelDrug="Caduet" section="34073-7">
<SentenceText>Concomitant administration of atorvastatin with inducers of CYP3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.</SentenceText>
<Mention id="M231" type="Trigger" span="116 35" str="reductions in plasma concentrations"/>
<Mention id="M228" type="Precipitant" span="74 9" str="efavirenz" code="JE6H2O27P8"/>
<Mention id="M230" type="Precipitant" span="48 18" str="inducers of CYP3A4" code="N0000185506"/>
<Mention id="M232" type="Precipitant" span="85 8" str="rifampin" code="VJT6J7R4TR"/>
<Interaction id="I101" type="Pharmacokinetic interaction" trigger="M231" precipitant="M228" effect="C54356"/>
<Interaction id="I102" type="Pharmacokinetic interaction" trigger="M231" precipitant="M230" effect="C54356"/>
<Interaction id="I103" type="Pharmacokinetic interaction" trigger="M231" precipitant="M232" effect="C54356"/>
</Sentence>
<Sentence id="1898" LabelDrug="Caduet" section="34073-7">
<SentenceText>Because of the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.</SentenceText>
<Mention id="M233" type="Trigger" span="246 9;272 21" str="reduction | plasma concentrations"/>
<Mention id="M234" type="Precipitant" span="45 8" str="rifampin" code="VJT6J7R4TR"/>
<Interaction id="I104" type="Pharmacokinetic interaction" trigger="M233" precipitant="M234" effect="C54356"/>
</Sentence>
<Sentence id="1899" LabelDrug="Caduet" section="34073-7">
<SentenceText>When multiple doses of atorvastatin and digoxin were co-administered, steady-state plasma digoxin concentrations increased by approximately 20%.</SentenceText>
<Mention id="M235" type="Trigger" span="70 19;98 24" str="steady-state plasma | concentrations increased"/>
<Mention id="M236" type="Precipitant" span="40 7" str="digoxin" code="73K4184T59"/>
<Interaction id="I105" type="Pharmacokinetic interaction" trigger="M235" precipitant="M236" effect="C54357"/>
</Sentence>
<Sentence id="1900" LabelDrug="Caduet" section="34073-7">
<SentenceText>Co-administration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol.</SentenceText>
<Mention id="M239" type="Trigger" span="60 13" str="increased AUC"/>
<Mention id="M238" type="Precipitant" span="103 17" str="ethinyl estradiol" code="423D2T571U"/>
<Mention id="M240" type="Precipitant" span="85 13" str="norethindrone" code="T18F433X4S"/>
<Interaction id="I106" type="Pharmacokinetic interaction" trigger="M239" precipitant="M238" effect="C54613"/>
<Interaction id="I107" type="Pharmacokinetic interaction" trigger="M239" precipitant="M240" effect="C54613"/>
</Sentence>
<Sentence id="1901" LabelDrug="Caduet" section="34073-7">
<SentenceText>Consider these increases when selecting an oral contraceptive for a woman taking CADUET.</SentenceText>
</Sentence>
<Sentence id="1902" LabelDrug="Caduet" section="34073-7">
<SentenceText>Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.</SentenceText>
</Sentence>
<Sentence id="1903" LabelDrug="Caduet" section="34073-7">
<SentenceText>Cases of myopathy, including rhabdomyolysis, have been reported with atorvastatin co-administered with colchicine.</SentenceText>
<Mention id="M245" type="Trigger" span="9 8" str="myopathy "/>
<Mention id="M246" type="Trigger" span="29 14" str=" rhabdomyolysis"/>
<Mention id="M247" type="Precipitant" span="103 10" str="colchicine" code="SML2Y3J35T"/>
<Mention id="M244" type="SpecificInteraction" span="29 14" str="rhabdomyolysis" code="240131006: Rhabdomyolysis (disorder)"/>
<Mention id="M248" type="SpecificInteraction" span="9 8" str="myopathy" code="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<Interaction id="I108" type="Pharmacodynamic interaction" trigger="M245;M246" precipitant="M247" effect="M244"/>
<Interaction id="I109" type="Pharmacodynamic interaction" trigger="M245;M246" precipitant="M247" effect="M248"/>
</Sentence>
<Sentence id="1904" LabelDrug="Caduet" section="43685-7">
<SentenceText>Myopathy and Rhabdomyolysis: Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness.</SentenceText>
</Sentence>
<Sentence id="1905" LabelDrug="Caduet" section="43685-7">
<SentenceText>CADUET therapy should be discontinued if myopathy is diagnosed or suspected (5.1, 8.5).</SentenceText>
</Sentence>
<Sentence id="1906" LabelDrug="Caduet" section="43685-7">
<SentenceText>Hepatic Transaminitis: Monitor liver enzymes before and during treatment (5.2).</SentenceText>
</Sentence>
<Sentence id="1907" LabelDrug="Caduet" section="43685-7">
<SentenceText>Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis.</SentenceText>
</Sentence>
<Sentence id="1908" LabelDrug="Caduet" section="43685-7">
<SentenceText>However, acute hypotension is unlikely (5.4).</SentenceText>
</Sentence>
<Sentence id="1909" LabelDrug="Caduet" section="43685-7">
<SentenceText>Angina or myocardial infarction may occur with initiation or dose increase (5.3).</SentenceText>
</Sentence>
<Sentence id="1910" LabelDrug="Caduet" section="43685-7">
<SentenceText>Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with atorvastatin and with other drugs in this class.</SentenceText>
</Sentence>
<Sentence id="1911" LabelDrug="Caduet" section="43685-7">
<SentenceText>A history of renal impairment may be a risk factor for the development of rhabdomyolysis.</SentenceText>
</Sentence>
<Sentence id="1912" LabelDrug="Caduet" section="43685-7">
<SentenceText>Such patients merit closer monitoring for skeletal muscle effects.</SentenceText>
</Sentence>
<Sentence id="1913" LabelDrug="Caduet" section="43685-7">
<SentenceText>Atorvastatin, like other statins, occasionally causes myopathy, defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values &gt; 10 times upper limit of normal [ULN].</SentenceText>
</Sentence>
<Sentence id="1914" LabelDrug="Caduet" section="43685-7">
<SentenceText>The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis.</SentenceText>
<Mention id="M291" type="Trigger" span="187 18" str="increases the risk"/>
<Mention id="M256" type="Precipitant" span="128 14" str="clarithromycin" code="H1250JIK0A"/>
<Mention id="M293" type="SpecificInteraction" span="209 23" str="myopathy/rhabdomyolysis" code="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<Mention id="M287" type="SpecificInteraction" span="218 14" str="rhabdomyolysis" code="240131006: Rhabdomyolysis (disorder)"/>
<Mention id="M290" type="SpecificInteraction" span="209 8" str="myopathy" code="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<Mention id="M265" type="Precipitant" span="79 12" str="cyclosporine" code="83HN0GTJ6D"/>
<Mention id="M274" type="Precipitant" span="162 23" str="HIV protease inhibitors" code="N0000000246"/>
<Mention id="M283" type="Precipitant" span="144 12" str="itraconazole" code="304NUG5GF4"/>
<Mention id="M292" type="Precipitant" span="96 24" str="strong CYP3A4 inhibitors" code="N0000182141"/>
<Interaction id="I110" type="Pharmacodynamic interaction" trigger="M291" precipitant="M256" effect="M293"/>
<Interaction id="I111" type="Pharmacodynamic interaction" trigger="M291" precipitant="M256" effect="M287"/>
<Interaction id="I112" type="Pharmacodynamic interaction" trigger="M291" precipitant="M256" effect="M290"/>
<Interaction id="I113" type="Pharmacodynamic interaction" trigger="M291" precipitant="M265" effect="M290"/>
<Interaction id="I114" type="Pharmacodynamic interaction" trigger="M291" precipitant="M265" effect="M293"/>
<Interaction id="I115" type="Pharmacodynamic interaction" trigger="M291" precipitant="M265" effect="M287"/>
<Interaction id="I116" type="Pharmacodynamic interaction" trigger="M291" precipitant="M274" effect="M293"/>
<Interaction id="I117" type="Pharmacodynamic interaction" trigger="M291" precipitant="M274" effect="M290"/>
<Interaction id="I118" type="Pharmacodynamic interaction" trigger="M291" precipitant="M274" effect="M287"/>
<Interaction id="I119" type="Pharmacodynamic interaction" trigger="M291" precipitant="M283" effect="M287"/>
<Interaction id="I120" type="Pharmacodynamic interaction" trigger="M291" precipitant="M283" effect="M290"/>
<Interaction id="I121" type="Pharmacodynamic interaction" trigger="M291" precipitant="M283" effect="M293"/>
<Interaction id="I122" type="Pharmacodynamic interaction" trigger="M291" precipitant="M292" effect="M287"/>
<Interaction id="I123" type="Pharmacodynamic interaction" trigger="M291" precipitant="M292" effect="M290"/>
<Interaction id="I124" type="Pharmacodynamic interaction" trigger="M291" precipitant="M292" effect="M293"/>
</Sentence>
<Sentence id="1915" LabelDrug="Caduet" section="43685-7">
<SentenceText>There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use.</SentenceText>
</Sentence>
<Sentence id="1916" LabelDrug="Caduet" section="43685-7">
<SentenceText>IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement with immunosuppressive agents.</SentenceText>
</Sentence>
<Sentence id="1917" LabelDrug="Caduet" section="43685-7">
<SentenceText>Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, or marked elevation of CPK.</SentenceText>
</Sentence>
<Sentence id="1918" LabelDrug="Caduet" section="43685-7">
<SentenceText>Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing CADUET.</SentenceText>
</Sentence>
<Sentence id="1919" LabelDrug="Caduet" section="43685-7">
<SentenceText>CADUET therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.</SentenceText>
</Sentence>
<Sentence id="1920" LabelDrug="Caduet" section="43685-7">
<SentenceText>The risk of myopathy during treatment with statins is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, the hepatitis C protease inhibitor telaprevir, combinations of HIV protease inhibitors, including saquinavir plus ritonavir, lopinavir plus ritonavir, tipranavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, and fosamprenavir plus ritonavir, niacin, or azole antifungals.</SentenceText>
<Mention id="M339" type="Trigger" span="4 4;54 9" str="risk | increased"/>
<Mention id="M295" type="Precipitant" span="431 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M341" type="SpecificInteraction" span="12 8" str="myopathy" code="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<Mention id="M298" type="Precipitant" span="151 14" str="clarithromycin" code="H1250JIK0A"/>
<Mention id="M301" type="Precipitant" span="214 39" str="combinations of HIV protease inhibitors" code="N0000000246"/>
<Mention id="M304" type="Precipitant" span="98 12" str="cyclosporine" code="83HN0GTJ6D"/>
<Mention id="M307" type="Precipitant" span="345 24" str="darunavir plus ritonavir" code="NO MAP"/>
<Mention id="M310" type="Precipitant" span="137 12" str="erythromycin" code="63937KV33D"/>
<Mention id="M313" type="Precipitant" span="112 23" str="fibric acid derivatives" code="6848ST447Q"/>
<Mention id="M316" type="Precipitant" span="371 13" str="fosamprenavir" code="WOU1621EEG"/>
<Mention id="M319" type="Precipitant" span="390 28" str="fosamprenavir plus ritonavir" code="NO MAP"/>
<Mention id="M322" type="Precipitant" span="171 30" str="hepatitis C protease inhibitor" code="N0000182639"/>
<Mention id="M325" type="Precipitant" span="171 41" str="hepatitis C protease inhibitor telaprevir" code="655M5O3W0U"/>
<Mention id="M328" type="Precipitant" span="292 24" str="lopinavir plus ritonavir" code="NO MAP"/>
<Mention id="M331" type="Precipitant" span="420 6" str="niacin" code="2679MF687A"/>
<Mention id="M334" type="Precipitant" span="265 25" str="saquinavir plus ritonavir" code="NO MAP"/>
<Mention id="M337" type="Precipitant" span="202 10" str="telaprevir" code="655M5O3W0U"/>
<Mention id="M340" type="Precipitant" span="318 25" str="tipranavir plus ritonavir" code="NO MAP"/>
<Interaction id="I125" type="Pharmacodynamic interaction" trigger="M339" precipitant="M295" effect="M341"/>
<Interaction id="I126" type="Pharmacodynamic interaction" trigger="M339" precipitant="M298" effect="M341"/>
<Interaction id="I127" type="Pharmacodynamic interaction" trigger="M339" precipitant="M301" effect="M341"/>
<Interaction id="I128" type="Pharmacodynamic interaction" trigger="M339" precipitant="M304" effect="M341"/>
<Interaction id="I129" type="Pharmacodynamic interaction" trigger="M339" precipitant="M307" effect="M341"/>
<Interaction id="I130" type="Pharmacodynamic interaction" trigger="M339" precipitant="M310" effect="M341"/>
<Interaction id="I131" type="Pharmacodynamic interaction" trigger="M339" precipitant="M313" effect="M341"/>
<Interaction id="I132" type="Pharmacodynamic interaction" trigger="M339" precipitant="M316" effect="M341"/>
<Interaction id="I133" type="Pharmacodynamic interaction" trigger="M339" precipitant="M319" effect="M341"/>
<Interaction id="I134" type="Pharmacodynamic interaction" trigger="M339" precipitant="M322" effect="M341"/>
<Interaction id="I135" type="Pharmacodynamic interaction" trigger="M339" precipitant="M325" effect="M341"/>
<Interaction id="I136" type="Pharmacodynamic interaction" trigger="M339" precipitant="M328" effect="M341"/>
<Interaction id="I137" type="Pharmacodynamic interaction" trigger="M339" precipitant="M331" effect="M341"/>
<Interaction id="I138" type="Pharmacodynamic interaction" trigger="M339" precipitant="M334" effect="M341"/>
<Interaction id="I139" type="Pharmacodynamic interaction" trigger="M339" precipitant="M337" effect="M341"/>
<Interaction id="I140" type="Pharmacodynamic interaction" trigger="M339" precipitant="M340" effect="M341"/>
</Sentence>
<Sentence id="1921" LabelDrug="Caduet" section="43685-7">
<SentenceText>Physicians considering combined therapy with CADUET and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug.</SentenceText>
<Mention id="M458" type="Trigger" span="376 17" str="carefully monitor "/>
<Mention id="M459" type="Trigger" span="411 17" str=" signs or symptoms"/>
<Mention id="M352" type="Precipitant" span="255 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M461" type="SpecificInteraction" span="445 10" str="tenderness" code="247348008: Tenderness (finding)"/>
<Mention id="M457" type="SpecificInteraction" span="432 11" str="muscle pain" code="68962001: Muscle pain (finding)"/>
<Mention id="M453" type="SpecificInteraction" span="460 8" str="weakness" code="13791008:  Asthenia (finding)"/>
<Mention id="M364" type="Precipitant" span="95 14" str="clarithromycin" code="H1250JIK0A"/>
<Mention id="M376" type="Precipitant" span="181 24" str="darunavir plus ritonavir" code="NO MAP"/>
<Mention id="M388" type="Precipitant" span="81 12" str="erythromycin" code="63937KV33D"/>
<Mention id="M400" type="Precipitant" span="56 23" str="fibric acid derivatives" code="6848ST447Q"/>
<Mention id="M412" type="Precipitant" span="207 13" str="fosamprenavir" code="WOU1621EEG"/>
<Mention id="M424" type="Precipitant" span="225 28" str="fosamprenavir plus ritonavir" code="NO MAP"/>
<Mention id="M436" type="Precipitant" span="277 31" str="lipid-modifying doses of niacin" code="2679MF687A"/>
<Mention id="M448" type="Precipitant" span="155 24" str="lopinavir plus ritonavir" code="NO MAP"/>
<Mention id="M460" type="Precipitant" span="128 25" str="saquinavir plus ritonavir" code="NO MAP"/>
<Interaction id="I141" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M352" effect="M461"/>
<Interaction id="I142" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M352" effect="M457"/>
<Interaction id="I143" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M352" effect="M453"/>
<Interaction id="I144" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M364" effect="M457"/>
<Interaction id="I145" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M364" effect="M461"/>
<Interaction id="I146" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M364" effect="M453"/>
<Interaction id="I147" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M376" effect="M457"/>
<Interaction id="I148" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M376" effect="M453"/>
<Interaction id="I149" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M376" effect="M461"/>
<Interaction id="I150" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M388" effect="M461"/>
<Interaction id="I151" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M388" effect="M453"/>
<Interaction id="I152" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M388" effect="M457"/>
<Interaction id="I153" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M400" effect="M457"/>
<Interaction id="I154" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M400" effect="M461"/>
<Interaction id="I155" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M400" effect="M453"/>
<Interaction id="I156" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M412" effect="M461"/>
<Interaction id="I157" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M412" effect="M453"/>
<Interaction id="I158" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M412" effect="M457"/>
<Interaction id="I159" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M424" effect="M461"/>
<Interaction id="I160" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M424" effect="M453"/>
<Interaction id="I161" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M424" effect="M457"/>
<Interaction id="I162" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M436" effect="M453"/>
<Interaction id="I163" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M436" effect="M461"/>
<Interaction id="I164" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M436" effect="M457"/>
<Interaction id="I165" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M448" effect="M453"/>
<Interaction id="I166" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M448" effect="M457"/>
<Interaction id="I167" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M448" effect="M461"/>
<Interaction id="I168" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M460" effect="M453"/>
<Interaction id="I169" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M460" effect="M457"/>
<Interaction id="I170" type="Pharmacodynamic interaction" trigger="M458;M459" precipitant="M460" effect="M461"/>
</Sentence>
<Sentence id="1922" LabelDrug="Caduet" section="43685-7">
<SentenceText>Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs.</SentenceText>
</Sentence>
<Sentence id="1923" LabelDrug="Caduet" section="43685-7">
<SentenceText>Periodic creatine phosphokinase (CPK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe myopathy.</SentenceText>
</Sentence>
<Sentence id="1924" LabelDrug="Caduet" section="43685-7">
<SentenceText>Prescribing recommendations for interacting agents are summarized in Table 2.</SentenceText>
</Sentence>
<Sentence id="1925" LabelDrug="Caduet" section="43685-7">
<SentenceText>Atorvastatin Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir) Avoid atorvastatin HIV protease inhibitor (lopinavir plus ritonavir) Use with caution and lowest dose necessary Clarithromycin, itraconazole,HIV protease inhibitors (saquinavir plus ritonavirUse with caution and with the lowest dose necessary (12.3), darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir) Do not exceed 20 mg atorvastatin daily HIV protease inhibitor (nelfinavir)Hepatitis C protease inhibitor (boceprevir) Do not exceed 40 mg atorvastatin daily Cases of myopathy, including rhabdomyolysis, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine.</SentenceText>
<Mention id="M650" type="Trigger" span="31 15" str="Associated with "/>
<Mention id="M651" type="Trigger" span="47 14" str=" Increased Risk"/>
<Mention id="M655" type="Precipitant" span="628 10" str="boceprevir" code="89BT58KELH"/>
<Mention id="M645" type="SpecificInteraction" span="-1 23" str="myopathy/rhabdomyolysis" code="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<Mention id="M649" type="SpecificInteraction" span="688 8" str="myopathy" code="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<Mention id="M653" type="SpecificInteraction" span="708 14" str="rhabdomyolysis" code="240131006: Rhabdomyolysis (disorder)"/>
<Mention id="M657" type="Precipitant" span="312 14" str="Clarithromycin" code="H1250JIK0A"/>
<Mention id="M496" type="Precipitant" span="782 10" str="colchicine" code="SML2Y3J35T"/>
<Mention id="M508" type="Precipitant" span="89 12" str="Cyclosporine" code="83HN0GTJ6D"/>
<Mention id="M659" type="Precipitant" span="451 24" str="darunavir plus ritonavir" code="NO MAP"/>
<Mention id="M661" type="Precipitant" span="477 13" str="fosamprenavir" code="WOU1621EEG"/>
<Mention id="M663" type="Precipitant" span="492 28" str="fosamprenavir plus ritonavir" code="NO MAP"/>
<Mention id="M556" type="Precipitant" span="156 30" str="hepatitis C protease inhibitor" code="N0000182639"/>
<Mention id="M669" type="Precipitant" span="103 22" str="HIV protease inhibitor" code="N0000000246"/>
<Mention id="M671" type="Precipitant" span="103 23" str="HIV protease inhibitors" code="N0000000246"/>
<Mention id="M673" type="Precipitant" span="328 12" str="itraconazole" code="304NUG5GF4"/>
<Mention id="M675" type="Precipitant" span="243 24" str="lopinavir plus ritonavir" code="NO MAP"/>
<Mention id="M677" type="Precipitant" span="585 10" str="nelfinavir" code="HO3OGH5D7I"/>
<Mention id="M679" type="Precipitant" span="366 25" str="saquinavir plus ritonavir" code="NO MAP"/>
<Mention id="M640" type="Precipitant" span="188 10" str="telaprevir" code="655M5O3W0U"/>
<Mention id="M652" type="Precipitant" span="128 25" str="tipranavir plus ritonavir" code="NO MAP"/>
<Mention id="M676" type="Trigger" span="522 13" str="Do not exceed"/>
<Mention id="M678" type="Trigger" span="290 21" str="lowest dose necessary"/>
<Mention id="M665" type="Precipitant" span="596 30" str="Hepatitis C protease inhibitor" code="N0000182639"/>
<Interaction id="I171" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M655" effect="M645"/>
<Interaction id="I172" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M655" effect="M649"/>
<Interaction id="I173" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M655" effect="M653"/>
<Interaction id="I174" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M657" effect="M645"/>
<Interaction id="I175" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M657" effect="M649"/>
<Interaction id="I176" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M657" effect="M653"/>
<Interaction id="I177" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M496" effect="M645"/>
<Interaction id="I178" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M496" effect="M649"/>
<Interaction id="I179" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M496" effect="M653"/>
<Interaction id="I180" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M508" effect="M653"/>
<Interaction id="I181" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M508" effect="M645"/>
<Interaction id="I182" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M508" effect="M649"/>
<Interaction id="I183" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M659" effect="M645"/>
<Interaction id="I184" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M659" effect="M653"/>
<Interaction id="I185" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M659" effect="M649"/>
<Interaction id="I186" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M661" effect="M645"/>
<Interaction id="I187" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M661" effect="M653"/>
<Interaction id="I188" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M661" effect="M649"/>
<Interaction id="I189" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M663" effect="M649"/>
<Interaction id="I190" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M663" effect="M653"/>
<Interaction id="I191" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M663" effect="M645"/>
<Interaction id="I192" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M556" effect="M653"/>
<Interaction id="I193" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M556" effect="M645"/>
<Interaction id="I194" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M556" effect="M649"/>
<Interaction id="I195" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M669" effect="M653"/>
<Interaction id="I196" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M669" effect="M649"/>
<Interaction id="I197" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M669" effect="M645"/>
<Interaction id="I198" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M671" effect="M645"/>
<Interaction id="I199" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M671" effect="M653"/>
<Interaction id="I200" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M671" effect="M649"/>
<Interaction id="I201" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M673" effect="M649"/>
<Interaction id="I202" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M673" effect="M653"/>
<Interaction id="I203" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M673" effect="M645"/>
<Interaction id="I204" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M675" effect="M653"/>
<Interaction id="I205" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M675" effect="M645"/>
<Interaction id="I206" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M675" effect="M649"/>
<Interaction id="I207" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M677" effect="M649"/>
<Interaction id="I208" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M677" effect="M645"/>
<Interaction id="I209" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M677" effect="M653"/>
<Interaction id="I210" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M679" effect="M645"/>
<Interaction id="I211" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M679" effect="M649"/>
<Interaction id="I212" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M679" effect="M653"/>
<Interaction id="I213" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M640" effect="M653"/>
<Interaction id="I214" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M640" effect="M645"/>
<Interaction id="I215" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M640" effect="M649"/>
<Interaction id="I216" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M652" effect="M645"/>
<Interaction id="I217" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M652" effect="M649"/>
<Interaction id="I218" type="Pharmacodynamic interaction" trigger="M650;M651" precipitant="M652" effect="M653"/>
<Interaction id="I219" type="Pharmacokinetic interaction" trigger="M676" precipitant="M655" effect="C54355"/>
<Interaction id="I220" type="Pharmacokinetic interaction" trigger="M678" precipitant="M657" effect="C54355"/>
<Interaction id="I221" type="Pharmacokinetic interaction" trigger="M678" precipitant="M659" effect="C54355"/>
<Interaction id="I222" type="Pharmacokinetic interaction" trigger="M678" precipitant="M661" effect="C54355"/>
<Interaction id="I223" type="Pharmacokinetic interaction" trigger="M678" precipitant="M663" effect="C54355"/>
<Interaction id="I224" type="Pharmacokinetic interaction" trigger="M676" precipitant="M665" effect="C54355"/>
<Interaction id="I225" type="Pharmacokinetic interaction" trigger="M676" precipitant="M669" effect="C54355"/>
<Interaction id="I226" type="Pharmacokinetic interaction" trigger="M678" precipitant="M669" effect="C54355"/>
<Interaction id="I227" type="Pharmacokinetic interaction" trigger="M678" precipitant="M671" effect="C54355"/>
<Interaction id="I228" type="Pharmacokinetic interaction" trigger="M678" precipitant="M673" effect="C54355"/>
<Interaction id="I229" type="Pharmacokinetic interaction" trigger="M678" precipitant="M675" effect="C54355"/>
<Interaction id="I230" type="Pharmacokinetic interaction" trigger="M676" precipitant="M677" effect="C54355"/>
<Interaction id="I231" type="Pharmacokinetic interaction" trigger="M678" precipitant="M679" effect="C54355"/>
</Sentence>
<Sentence id="1926" LabelDrug="Caduet" section="43685-7">
<SentenceText>Withhold or discontinue in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection; hypotension; major surgery; trauma; severe metabolic, endocrine, and electrolyte disorders; and uncontrolled seizures).</SentenceText>
</Sentence>
<Sentence id="1927" LabelDrug="Caduet" section="43685-7">
<SentenceText>Statins, like atorvastatin, and some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function.</SentenceText>
</Sentence>
<Sentence id="1928" LabelDrug="Caduet" section="43685-7">
<SentenceText>Persistent elevations (&gt; 3 times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin in clinical trials.</SentenceText>
</Sentence>
<Sentence id="1929" LabelDrug="Caduet" section="43685-7">
<SentenceText>The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively.</SentenceText>
</Sentence>
<Sentence id="1930" LabelDrug="Caduet" section="43685-7">
<SentenceText>One patient in clinical trials with atorvastatin developed jaundice.</SentenceText>
</Sentence>
<Sentence id="1931" LabelDrug="Caduet" section="43685-7">
<SentenceText>Increases in liver function tests (LFT) in other patients were not associated with jaundice or other clinical signs or symptoms.</SentenceText>
</Sentence>
<Sentence id="1932" LabelDrug="Caduet" section="43685-7">
<SentenceText>Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae.</SentenceText>
</Sentence>
<Sentence id="1933" LabelDrug="Caduet" section="43685-7">
<SentenceText>Eighteen of 30 patients with persistent LFT elevations continued treatment with a reduced dose of atorvastatin.</SentenceText>
</Sentence>
<Sentence id="1934" LabelDrug="Caduet" section="43685-7">
<SentenceText>It is recommended that liver enzyme tests be obtained prior to initiating therapy with atorvastatin and repeated as clinically indicated.</SentenceText>
</Sentence>
<Sentence id="1935" LabelDrug="Caduet" section="43685-7">
<SentenceText>There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including atorvastatin.</SentenceText>
</Sentence>
<Sentence id="1936" LabelDrug="Caduet" section="43685-7">
<SentenceText>If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with CADUET, promptly interrupt therapy.</SentenceText>
</Sentence>
<Sentence id="1937" LabelDrug="Caduet" section="43685-7">
<SentenceText>If an alternate etiology is not found, do not restart CADUET.</SentenceText>
</Sentence>
<Sentence id="1938" LabelDrug="Caduet" section="43685-7">
<SentenceText>Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of CADUET.</SentenceText>
</Sentence>
<Sentence id="1939" LabelDrug="Caduet" section="43685-7">
<SentenceText>Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of amlodipine, particularly in patients with severe obstructive coronary artery disease.</SentenceText>
</Sentence>
<Sentence id="1940" LabelDrug="Caduet" section="43685-7">
<SentenceText>Symptomatic hypotension is possible with use of amlodipine, particularly in patients with severe aortic stenosis.</SentenceText>
</Sentence>
<Sentence id="1941" LabelDrug="Caduet" section="43685-7">
<SentenceText>Because of the gradual onset of action, acute hypotension is unlikely.</SentenceText>
</Sentence>
<Sentence id="1942" LabelDrug="Caduet" section="43685-7">
<SentenceText>Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including atorvastatin.</SentenceText>
</Sentence>
<Sentence id="1943" LabelDrug="Caduet" section="43685-7">
<SentenceText>Statins interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production.</SentenceText>
</Sentence>
<Sentence id="1944" LabelDrug="Caduet" section="43685-7">
<SentenceText>Clinical studies have shown that atorvastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve.</SentenceText>
</Sentence>
<Sentence id="1945" LabelDrug="Caduet" section="43685-7">
<SentenceText>The effects of statins on male fertility have not been studied in adequate numbers of patients.</SentenceText>
</Sentence>
<Sentence id="1946" LabelDrug="Caduet" section="43685-7">
<SentenceText>The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown.</SentenceText>
</Sentence>
<Sentence id="1947" LabelDrug="Caduet" section="43685-7">
<SentenceText>Avoid a statin with drugs that may decrease the levels or activity of endogenous steroid hormones such as ketoconazole, spironolactone, and cimetidine.</SentenceText>
<Mention id="M686" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M681" type="Precipitant" span="140 10" str="cimetidine" code="80061L1WGD"/>
<Mention id="M683" type="Precipitant" span="20 77" str="drugs that may decrease the levels or activity of endogenous steroid hormones" code="NO MAP"/>
<Mention id="M685" type="Precipitant" span="106 12" str="ketoconazole" code="R9400W927I"/>
<Mention id="M687" type="Precipitant" span="120 14" str="spironolactone" code="27O7W4T232"/>
<Interaction id="I232" type="Unspecified interaction" trigger="M686" precipitant="M681"/>
<Interaction id="I233" type="Unspecified interaction" trigger="M686" precipitant="M683"/>
<Interaction id="I234" type="Unspecified interaction" trigger="M686" precipitant="M685"/>
<Interaction id="I235" type="Unspecified interaction" trigger="M686" precipitant="M687"/>
</Sentence>
<Sentence id="1948" LabelDrug="Caduet" section="43685-7">
<SentenceText>Brain hemorrhage was seen in a female dog treated with atorvastatin for 3 months at 120 mg/kg/day.</SentenceText>
</Sentence>
<Sentence id="1949" LabelDrug="Caduet" section="43685-7">
<SentenceText>Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day.</SentenceText>
</Sentence>
<Sentence id="1950" LabelDrug="Caduet" section="43685-7">
<SentenceText>The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0–24 hours) based on the maximum human dose of 80 mg/day.</SentenceText>
</Sentence>
<Sentence id="1951" LabelDrug="Caduet" section="43685-7">
<SentenceText>A single tonic convulsion was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study.</SentenceText>
</Sentence>
<Sentence id="1952" LabelDrug="Caduet" section="43685-7">
<SentenceText>No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day.</SentenceText>
</Sentence>
<Sentence id="1953" LabelDrug="Caduet" section="43685-7">
<SentenceText>These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0–24) based on the maximum recommended human dose (MRHD) of 80 mg/day.</SentenceText>
</Sentence>
<Sentence id="1954" LabelDrug="Caduet" section="43685-7">
<SentenceText>CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other statins.</SentenceText>
</Sentence>
<Sentence id="1955" LabelDrug="Caduet" section="43685-7">
<SentenceText>A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose.</SentenceText>
</Sentence>
<Sentence id="1956" LabelDrug="Caduet" section="43685-7">
<SentenceText>In a post-hoc analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study where atorvastatin 80 mg vs. placebo was administered in 4,731 subjects without CHD who had a stroke or TIA within the preceding 6 months, a higher incidence of hemorrhagic stroke was seen in the atorvastatin 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168).</SentenceText>
</Sentence>
<Sentence id="1957" LabelDrug="Caduet" section="43685-7">
<SentenceText>The incidence of fatal hemorrhagic stroke was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively).</SentenceText>
</Sentence>
<Sentence id="1958" LabelDrug="Caduet" section="43685-7">
<SentenceText>The incidence of non-fatal hemorrhagic stroke was significantly higher in the atorvastatin group (38, 1.6%) as compared to the placebo group (16, 0.7%).</SentenceText>
</Sentence>
<Sentence id="1959" LabelDrug="Caduet" section="43685-7">
<SentenceText>Some baseline characteristics, including hemorrhagic and lacunar stroke on study entry, were associated with a higher incidence of hemorrhagic stroke in the atorvastatin group.</SentenceText>
</Sentence>
<Sentence id="1960" LabelDrug="Caduet" section="34090-1">
<SentenceText>CADUET is a combination of two drugs, a dihydropyridine calcium channel blocker (amlodipine) and an HMG-CoA reductase inhibitor (atorvastatin).</SentenceText>
</Sentence>
<Sentence id="1961" LabelDrug="Caduet" section="34090-1">
<SentenceText>The amlodipine component of CADUET inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle.</SentenceText>
</Sentence>
<Sentence id="1962" LabelDrug="Caduet" section="34090-1">
<SentenceText>The atorvastatin component of CADUET is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol.</SentenceText>
</Sentence>
<Sentence id="1963" LabelDrug="Caduet" section="34090-1">
<SentenceText>Amlodipine Amlodipine binds to both dihydropyridine and nondihydropyridine binding sites.</SentenceText>
</Sentence>
<Sentence id="1964" LabelDrug="Caduet" section="34090-1">
<SentenceText>The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.</SentenceText>
</Sentence>
<Sentence id="1965" LabelDrug="Caduet" section="34090-1">
<SentenceText>Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells.</SentenceText>
</Sentence>
<Sentence id="1966" LabelDrug="Caduet" section="34090-1">
<SentenceText>Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses.</SentenceText>
</Sentence>
<Sentence id="1967" LabelDrug="Caduet" section="34090-1">
<SentenceText>Serum calcium concentration is not affected by amlodipine.</SentenceText>
</Sentence>
<Sentence id="1968" LabelDrug="Caduet" section="34090-1">
<SentenceText>Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.</SentenceText>
</Sentence>
<Sentence id="1969" LabelDrug="Caduet" section="34090-1">
<SentenceText>The precise mechanisms by which amlodipine relieves angina have not been fully delineated, but are thought to include the following: Exertional Angina: In patients with exertional angina, amlodipine reduces the total peripheral resistance (afterload) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise.</SentenceText>
</Sentence>
<Sentence id="1970" LabelDrug="Caduet" section="34090-1">
<SentenceText>Vasospastic Angina: Amlodipine has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels in vitro.</SentenceText>
</Sentence>
<Sentence id="1971" LabelDrug="Caduet" section="34090-1">
<SentenceText>This inhibition of coronary spasm is responsible for the effectiveness of amlodipine in vasospastic (Prinzmetal's or variant) angina.</SentenceText>
</Sentence>
<Sentence id="1972" LabelDrug="Caduet" section="34090-1">
<SentenceText>Atorvastatin Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol.</SentenceText>
</Sentence>
<Sentence id="1973" LabelDrug="Caduet" section="34090-1">
<SentenceText>In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles.</SentenceText>
</Sentence>
<Sentence id="1974" LabelDrug="Caduet" section="34090-1">
<SentenceText>Amlodipine Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation resulting in a reduction of supine and standing blood pressures.</SentenceText>
</Sentence>
<Sentence id="1975" LabelDrug="Caduet" section="34090-1">
<SentenceText>These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing.</SentenceText>
</Sentence>
<Sentence id="1976" LabelDrug="Caduet" section="34090-1">
<SentenceText>Although the acute intravenous administration of amlodipine decreases arterial blood pressure and increases heart rate in hemodynamic studies of patients with chronic stable angina, chronic oral administration of amlodipine in clinical trials did not lead to clinically significant changes in heart rate or blood pressures in normotensive patients with angina.</SentenceText>
</Sentence>
<Sentence id="1977" LabelDrug="Caduet" section="34090-1">
<SentenceText>With chronic once daily oral administration, antihypertensive effectiveness is maintained for at least 24 hours.</SentenceText>
</Sentence>
<Sentence id="1978" LabelDrug="Caduet" section="34090-1">
<SentenceText>Plasma concentrations correlate with effect in both young and elderly patients.</SentenceText>
</Sentence>
<Sentence id="1979" LabelDrug="Caduet" section="34090-1">
<SentenceText>The magnitude of reduction in blood pressure with amlodipine is also correlated with the height of pretreatment elevation; thus, individuals with moderate hypertension (diastolic pressure 105–114 mmHg) had about a 50% greater response than patients with mild hypertension (diastolic pressure 90–104 mmHg).</SentenceText>
</Sentence>
<Sentence id="1980" LabelDrug="Caduet" section="34090-1">
<SentenceText>Normotensive subjects experienced no clinically significant change in blood pressures (+1/–2 mmHg).</SentenceText>
</Sentence>
<Sentence id="1981" LabelDrug="Caduet" section="34090-1">
<SentenceText>In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal plasma flow without change in filtration fraction or proteinuria.</SentenceText>
</Sentence>
<Sentence id="1982" LabelDrug="Caduet" section="34090-1">
<SentenceText>As with other calcium channel blockers, hemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have generally demonstrated a small increase in cardiac index without significant influence on dP/dt or on left ventricular end diastolic pressure or volume.</SentenceText>
</Sentence>
<Sentence id="1983" LabelDrug="Caduet" section="34090-1">
<SentenceText>In hemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and man, even when co-administered with beta-blockers to man.</SentenceText>
</Sentence>
<Sentence id="1984" LabelDrug="Caduet" section="34090-1">
<SentenceText>Similar findings, however, have been observed in normal or well-compensated patients with heart failure with agents possessing significant negative inotropic effects.</SentenceText>
</Sentence>
<Sentence id="1985" LabelDrug="Caduet" section="34090-1">
<SentenceText>Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals or man.</SentenceText>
</Sentence>
<Sentence id="1986" LabelDrug="Caduet" section="34090-1">
<SentenceText>In patients with chronic stable angina, intravenous administration of 10 mg did not significantly alter A-H and H-V conduction and sinus node recovery time after pacing.</SentenceText>
</Sentence>
<Sentence id="1987" LabelDrug="Caduet" section="34090-1">
<SentenceText>Similar results were obtained in patients receiving amlodipine and concomitant beta-blockers.</SentenceText>
</Sentence>
<Sentence id="1988" LabelDrug="Caduet" section="34090-1">
<SentenceText>In clinical studies in which amlodipine was administered in combination with beta-blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed.</SentenceText>
</Sentence>
<Sentence id="1989" LabelDrug="Caduet" section="34090-1">
<SentenceText>In clinical trials with angina patients alone, amlodipine therapy did not alter electrocardiographic intervals or produce higher degrees of AV blocks.</SentenceText>
</Sentence>
<Sentence id="1990" LabelDrug="Caduet" section="34090-1">
<SentenceText>Atorvastatin Atorvastatin, as well as some of its metabolites, are pharmacologically active in humans.</SentenceText>
</Sentence>
<Sentence id="1991" LabelDrug="Caduet" section="34090-1">
<SentenceText>The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance.</SentenceText>
</Sentence>
<Sentence id="1992" LabelDrug="Caduet" section="34090-1">
<SentenceText>Drug dosage, rather than systemic drug concentration, correlates better with LDL-C reduction.</SentenceText>
</Sentence>
<Sentence id="1993" LabelDrug="Caduet" section="34090-1">
<SentenceText>Individualization of drug dosage should be based on therapeutic response.</SentenceText>
</Sentence>
<Sentence id="1994" LabelDrug="Caduet" section="34090-1">
<SentenceText>Drug interactions Sildenafil: When amlodipine and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.</SentenceText>
</Sentence>
<Sentence id="1995" LabelDrug="Caduet" section="34090-1">
<SentenceText>Absorption Amlodipine: After oral administration of therapeutic doses of amlodipine alone, absorption produces peak plasma concentrations between 6 and 12 hours.</SentenceText>
</Sentence>
<Sentence id="1996" LabelDrug="Caduet" section="34090-1">
<SentenceText>Absolute bioavailability has been estimated to be between 64% and 90%.</SentenceText>
</Sentence>
<Sentence id="1997" LabelDrug="Caduet" section="34090-1">
<SentenceText>Atorvastatin: After oral administration alone, atorvastatin is rapidly absorbed; maximum plasma concentrations occur within 1 to 2 hours.</SentenceText>
</Sentence>
<Sentence id="1998" LabelDrug="Caduet" section="34090-1">
<SentenceText>Extent of absorption increases in proportion to atorvastatin dose.</SentenceText>
</Sentence>
<Sentence id="1999" LabelDrug="Caduet" section="34090-1">
<SentenceText>The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.</SentenceText>
</Sentence>
<Sentence id="2000" LabelDrug="Caduet" section="34090-1">
<SentenceText>The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism.</SentenceText>
</Sentence>
<Sentence id="2001" LabelDrug="Caduet" section="34090-1">
<SentenceText>Plasma atorvastatin concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning.</SentenceText>
</Sentence>
<Sentence id="2002" LabelDrug="Caduet" section="34090-1">
<SentenceText>However, LDL-C reduction is the same regardless of the time of day of drug administration.</SentenceText>
</Sentence>
<Sentence id="2003" LabelDrug="Caduet" section="34090-1">
<SentenceText>CADUET: Following oral administration of CADUET, peak plasma concentrations of amlodipine and atorvastatin are seen at 6 to 12 hours and 1 to 2 hours post dosing, respectively.</SentenceText>
</Sentence>
<Sentence id="2004" LabelDrug="Caduet" section="34090-1">
<SentenceText>The rate and extent of absorption (bioavailability) of amlodipine and atorvastatin from CADUET are not significantly different from the bioavailability of amlodipine and atorvastatin administered separately.</SentenceText>
</Sentence>
<Sentence id="2005" LabelDrug="Caduet" section="34090-1">
<SentenceText>The bioavailability of amlodipine from CADUET was not affected by food.</SentenceText>
</Sentence>
<Sentence id="2006" LabelDrug="Caduet" section="34090-1">
<SentenceText>Food decreases the rate and extent of absorption of atorvastatin from CADUET by approximately 32% and 11%, respectively, as it does with atorvastatin when given alone.</SentenceText>
<Mention id="M688" type="Trigger" span="5 9;38 10" str="decreases | absorption"/>
<Mention id="M689" type="Precipitant" span="0 4" str="Food" code="NO MAP"/>
<Interaction id="I236" type="Pharmacokinetic interaction" trigger="M688" precipitant="M689" effect="C54356"/>
</Sentence>
<Sentence id="2007" LabelDrug="Caduet" section="34090-1">
<SentenceText>LDL-C reduction is similar whether atorvastatin is given with or without food.</SentenceText>
</Sentence>
<Sentence id="2008" LabelDrug="Caduet" section="34090-1">
<SentenceText>Distribution Amlodipine: Ex vivo studies have shown that approximately 93% of the circulating amlodipine drug is bound to plasma proteins in hypertensive patients.</SentenceText>
</Sentence>
<Sentence id="2009" LabelDrug="Caduet" section="34090-1">
<SentenceText>Steady-state plasma levels of amlodipine are reached after 7 to 8 days of consecutive daily dosing.</SentenceText>
</Sentence>
<Sentence id="2010" LabelDrug="Caduet" section="34090-1">
<SentenceText>Atorvastatin: Mean volume of distribution of atorvastatin is approximately 381 liters.</SentenceText>
</Sentence>
<Sentence id="2011" LabelDrug="Caduet" section="34090-1">
<SentenceText>Atorvastatin is ≥98% bound to plasma proteins.</SentenceText>
</Sentence>
<Sentence id="2012" LabelDrug="Caduet" section="34090-1">
<SentenceText>A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells.</SentenceText>
</Sentence>
<Sentence id="2013" LabelDrug="Caduet" section="34090-1">
<SentenceText>Based on observations in rats, atorvastatin calcium is likely to be secreted in human milk.</SentenceText>
</Sentence>
<Sentence id="2014" LabelDrug="Caduet" section="34090-1">
<SentenceText>Metabolism Amlodipine: Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism.</SentenceText>
</Sentence>
<Sentence id="2015" LabelDrug="Caduet" section="34090-1">
<SentenceText>Atorvastatin: Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products.</SentenceText>
</Sentence>
<Sentence id="2016" LabelDrug="Caduet" section="34090-1">
<SentenceText>In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin.</SentenceText>
</Sentence>
<Sentence id="2017" LabelDrug="Caduet" section="34090-1">
<SentenceText>Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites.</SentenceText>
</Sentence>
<Sentence id="2018" LabelDrug="Caduet" section="34090-1">
<SentenceText>In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P4503A4, consistent with increased plasma concentrations of atorvastatin in humans following co-administration with erythromycin, a known inhibitor of this isozyme.</SentenceText>
<Mention id="M690" type="Trigger" span="106 31" str="increased plasma concentrations"/>
<Mention id="M691" type="Precipitant" span="197 12" str="erythromycin" code="63937KV33D"/>
<Interaction id="I237" type="Pharmacokinetic interaction" trigger="M690" precipitant="M691" effect="C54355"/>
</Sentence>
<Sentence id="2019" LabelDrug="Caduet" section="34090-1">
<SentenceText>In animals, the ortho-hydroxy metabolite undergoes further glucuronidation.</SentenceText>
</Sentence>
<Sentence id="2020" LabelDrug="Caduet" section="34090-1">
<SentenceText>Excretion Amlodipine: Elimination from the plasma is biphasic with a terminal elimination half-life of about 30–50 hours.</SentenceText>
</Sentence>
<Sentence id="2021" LabelDrug="Caduet" section="34090-1">
<SentenceText>Ten percent of the parent amlodipine compound and 60% of the metabolites of amlodipine are excreted in the urine.</SentenceText>
</Sentence>
<Sentence id="2022" LabelDrug="Caduet" section="34090-1">
<SentenceText>Atorvastatin: Atorvastatin and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation.</SentenceText>
</Sentence>
<Sentence id="2023" LabelDrug="Caduet" section="34090-1">
<SentenceText>Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours because of the contribution of active metabolites.</SentenceText>
</Sentence>
<Sentence id="2024" LabelDrug="Caduet" section="34090-1">
<SentenceText>Less than 2% of a dose of atorvastatin is recovered in urine following oral administration.</SentenceText>
</Sentence>
<Sentence id="2025" LabelDrug="Caduet" section="34090-1">
<SentenceText>Specific Populations Geriatric Amlodipine: Elderly patients have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40–60%, and a lower initial dose of amlodipine may be required.</SentenceText>
</Sentence>
<Sentence id="2026" LabelDrug="Caduet" section="34090-1">
<SentenceText>Atorvastatin: Plasma concentrations of atorvastatin are higher (approximately 40% for Cmax and 30% for AUC) in healthy elderly subjects (age ≥65 years) than in young adults.</SentenceText>
</Sentence>
<Sentence id="2027" LabelDrug="Caduet" section="34090-1">
<SentenceText>Clinical data suggest a greater degree of LDL-lowering at any dose of atorvastatin in the elderly population compared to younger adults.</SentenceText>
</Sentence>
<Sentence id="2028" LabelDrug="Caduet" section="34090-1">
<SentenceText>Pediatric Amlodipine: Sixty-two hypertensive patients aged 6 to 17 years received doses of amlodipine between 1.25 mg and 20 mg. Weight-adjusted clearance and volume of distribution were similar to values in adults.</SentenceText>
</Sentence>
<Sentence id="2029" LabelDrug="Caduet" section="34090-1">
<SentenceText>Atorvastatin: Apparent oral clearance of atorvastatin in pediatric subjects appeared similar to that of adults when scaled allometrically by body weight as the body weight was the only significant covariate in atorvastatin population pharmacokinetics model with data including pediatric HeFH patients (ages 10 years to 17 years of age, n=29) in an open-label, 8-week study.</SentenceText>
</Sentence>
<Sentence id="2030" LabelDrug="Caduet" section="34090-1">
<SentenceText>Gender Atorvastatin: Plasma concentrations of atorvastatin in women differ from those in men (approximately 20% higher for Cmax and 10% lower for AUC); however, there is no clinically significant difference in LDL-C reduction with atorvastatin between men and women.</SentenceText>
</Sentence>
<Sentence id="2031" LabelDrug="Caduet" section="34090-1">
<SentenceText>Renal Impairment Amlodipine: The pharmacokinetics of amlodipine are not significantly influenced by renal impairment.</SentenceText>
</Sentence>
<Sentence id="2032" LabelDrug="Caduet" section="34090-1">
<SentenceText>Patients with renal failure may therefore receive the usual initial amlodipine dose.</SentenceText>
</Sentence>
<Sentence id="2033" LabelDrug="Caduet" section="34090-1">
<SentenceText>Atorvastatin: Renal disease has no influence on the plasma concentrations or LDL-C reduction of atorvastatin; thus, dose adjustment of atorvastatin in patients with renal dysfunction is not necessary.</SentenceText>
</Sentence>
<Sentence id="2034" LabelDrug="Caduet" section="34090-1">
<SentenceText>Hemodialysis While studies have not been conducted in patients with end-stage renal disease, hemodialysis is not expected to clear atorvastatin or amlodipine since both drugs are extensively bound to plasma proteins.</SentenceText>
</Sentence>
<Sentence id="2035" LabelDrug="Caduet" section="34090-1">
<SentenceText>Hepatic Impairment Amlodipine: Elderly patients and patients with hepatic insufficiency have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40–60%.</SentenceText>
</Sentence>
<Sentence id="2036" LabelDrug="Caduet" section="34090-1">
<SentenceText>Atorvastatin: In patients with chronic alcoholic liver disease, plasma concentrations of atorvastatin are markedly increased.</SentenceText>
</Sentence>
<Sentence id="2037" LabelDrug="Caduet" section="34090-1">
<SentenceText>Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease.</SentenceText>
</Sentence>
<Sentence id="2038" LabelDrug="Caduet" section="34090-1">
<SentenceText>Cmax and AUC of atorvastatin are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease.</SentenceText>
</Sentence>
<Sentence id="2039" LabelDrug="Caduet" section="34090-1">
<SentenceText>Atorvastatin is contraindicated in patients with active liver disease.</SentenceText>
</Sentence>
<Sentence id="2040" LabelDrug="Caduet" section="34090-1">
<SentenceText>Heart Failure Amlodipine: In patients with moderate to severe heart failure, the increase in AUC for amlodipine was similar to that seen in the elderly and in patients with hepatic insufficiency.</SentenceText>
</Sentence>
<Sentence id="2041" LabelDrug="Caduet" section="34090-1">
<SentenceText>Effects of Other Drugs on CADUET Amlodipine: Co-administered cimetidine, magnesium-and aluminum hydroxide antacids, sildenafil, and grapefruit juice have no impact on the exposure to amlodipine.</SentenceText>
</Sentence>
<Sentence id="2042" LabelDrug="Caduet" section="34090-1">
<SentenceText>CYP3A inhibitors: Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure.</SentenceText>
<Mention id="M694" type="Trigger" span="144 8;167 17" str="increase | systemic exposure"/>
<Mention id="M693" type="Precipitant" span="0 16" str="CYP3A inhibitors" code="N0000191001"/>
<Mention id="M695" type="Precipitant" span="62 9" str="diltiazem" code="EE92BBP03H"/>
<Interaction id="I238" type="Pharmacokinetic interaction" trigger="M694" precipitant="M693" effect="C54355"/>
<Interaction id="I239" type="Pharmacokinetic interaction" trigger="M694" precipitant="M695" effect="C54355"/>
</Sentence>
<Sentence id="2043" LabelDrug="Caduet" section="34090-1">
<SentenceText>Erythromycin co-administration in healthy volunteers did not significantly change amlodipine systemic exposure.</SentenceText>
</Sentence>
<Sentence id="2044" LabelDrug="Caduet" section="34090-1">
<SentenceText>However, strong inhibitors of CYP3A (e.g., itraconazole, clarithromycin) may increase the plasma concentrations of amlodipine to a greater extent.</SentenceText>
<Mention id="M700" type="Trigger" span="77 34" str="increase the plasma concentrations"/>
<Mention id="M697" type="Precipitant" span="57 14" str="clarithromycin" code="H1250JIK0A"/>
<Mention id="M699" type="Precipitant" span="43 12" str="itraconazole" code="304NUG5GF4"/>
<Mention id="M701" type="Precipitant" span="9 26" str="strong inhibitors of CYP3A" code="N0000191001"/>
<Interaction id="I240" type="Pharmacokinetic interaction" trigger="M700" precipitant="M697" effect="C54355"/>
<Interaction id="I241" type="Pharmacokinetic interaction" trigger="M700" precipitant="M699" effect="C54355"/>
<Interaction id="I242" type="Pharmacokinetic interaction" trigger="M700" precipitant="M701" effect="C54355"/>
</Sentence>
<Sentence id="2045" LabelDrug="Caduet" section="34090-1">
<SentenceText>Atorvastatin: Table 4 shows effects of other drugs on the pharmacokinetics of atorvastatin.</SentenceText>
</Sentence>
<Sentence id="2046" LabelDrug="Caduet" section="34090-1">
<SentenceText>Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin Co-administered drug and dosing regimen Atorvastatin Dose (mg) Change in AUC Change in Cmax See Warnings and Precautions (5.1) and Drug Interactions (7) for clinical significance.Cyclosporine 5.2 mg/kg/day, stable dose 10 mg QD for 28 days ↑ 870% ↑1070% Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days 10 mg, SD ↑ 940% ↑ 860% Telaprevir 750 mg q8h, 10 days 20 mg, SD ↑ 790% ↑ 1060%, The dose of saquinavir plus ritonavir in this study is not the clinically used dose.</SentenceText>
</Sentence>
<Sentence id="2047" LabelDrug="Caduet" section="34090-1">
<SentenceText>The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study.</SentenceText>
</Sentence>
<Sentence id="2048" LabelDrug="Caduet" section="34090-1">
<SentenceText>Therefore, use the lowest dose necessary.Saquinavir 400 mg BID/ritonavir 400mg BID, 15 days 40 mg QD for 4 days ↑ 390% ↑ 430% Clarithromycin 500 mg BID, 9 days 80 mg QD for 8 days ↑ 440% ↑ 540% Darunavir 300 mg BID/ritonavir 100 mg BID, 9 days 10 mg QD for 4 days ↑ 340% ↑ 230% Itraconazole 200 mg QD, 4 days 40 mg SD ↑ 330% ↑ 20% Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days 10 mg QD for 4 days ↑ 250% ↑ 280% Fosamprenavir 1400 mg BID, 14 days 10 mg QD for 4 days ↑ 230% ↑ 400% Nelfinavir 1250 mg BID, 14 days 10 mg QD for 28 days ↑ 74% ↑ 220% Grapefruit Juice, 240 mL QDGreater increases in AUC (up to 2.5-fold) and/or Cmax (up to 71%) have been reported with excessive grapefruit consumption (≥ 750 mL – 1.2 liters per day).</SentenceText>
<Mention id="M702" type="Trigger" span="590 16" str="increases in AUC"/>
<Mention id="M703" type="Precipitant" span="672 20" str="excessive grapefruit" code="O82C39RR8C"/>
<Interaction id="I243" type="Pharmacokinetic interaction" trigger="M702" precipitant="M703" effect="C54605"/>
</Sentence>
<Sentence id="2049" LabelDrug="Caduet" section="34090-1">
<SentenceText>40 mg, SD ↑ 37% ↑ 16% Diltiazem 240 mg QD, 28 days 40 mg, SD ↑ 51% No change Erythromycin 500 mg QID, 7 days 10 mg, SD ↑ 33% ↑ 38% Amlodipine 10 mg, single dose 80 mg, SD ↑ 15% ↓ 12 % Cimetidine 300 mg QID, 2 weeks 10 mg QD for 2 weeks ↓ Less than 1% ↓ 11% Colestipol 10 mg BID, 28 weeks 40 mg QD for 28 weeks Not determined ↓ 26%Single sample taken 8–16 h post dose.</SentenceText>
</Sentence>
<Sentence id="2050" LabelDrug="Caduet" section="34090-1">
<SentenceText>Maalox TC® 30 mL QD, 17 days 10 mg QD for 15 days ↓ 33% ↓ 34% Efavirenz 600 mg QD, 14 days 10 mg for 3 days ↓ 41% ↓ 1% Rifampin 600 mg QD, 7 days (co-administered)Because of the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.</SentenceText>
<Mention id="M704" type="Trigger" span="409 9;435 21" str="reduction | plasma concentrations"/>
<Mention id="M705" type="Precipitant" span="208 8" str="rifampin" code="VJT6J7R4TR"/>
<Interaction id="I244" type="Pharmacokinetic interaction" trigger="M704" precipitant="M705" effect="C54356"/>
</Sentence>
<Sentence id="2051" LabelDrug="Caduet" section="34090-1">
<SentenceText>40 mg SD ↑ 30% ↑ 2.7-fold Rifampin 600 mg QD, 5 days (doses separated) 40 mg SD ↓ 80% ↓ 40% Gemfibrozil 600 mg BID, 7 days 40mg SD ↑ 35% ↓ Less than 1% Fenofibrate 160 mg QD, 7 days 40mg SD ↑ 3% ↑ 2% Boceprevir 800 mg TID, 7 days 40 mg SD ↑2.30 fold ↑2.66 fold Effects of CADUET on Other Drugs Amlodipine: Amlodipine is a weak inhibitor of CYP3A and may increase exposure to CYP3A substrates.</SentenceText>
<Mention id="M706" type="Trigger" span="354 17" str="increase exposure"/>
<Mention id="M707" type="Precipitant" span="375 16" str="CYP3A substrates" code="NO MAP"/>
<Interaction id="I245" type="Pharmacokinetic interaction" trigger="M706" precipitant="M707" effect="C54357"/>
</Sentence>
<Sentence id="2052" LabelDrug="Caduet" section="34090-1">
<SentenceText>In vitro data indicate that amlodipine has no effect on the human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin.</SentenceText>
</Sentence>
<Sentence id="2053" LabelDrug="Caduet" section="34090-1">
<SentenceText>Co-administered amlodipine does not affect the exposure to atorvastatin, digoxin, ethanol and the warfarin prothrombin response time.</SentenceText>
</Sentence>
<Sentence id="2054" LabelDrug="Caduet" section="34090-1">
<SentenceText>Cyclosporine: A prospective study in renal transplant patients (N=11) showed on an average of 40% increase in trough cyclosporine levels when concomitantly treated with amlodipine.</SentenceText>
<Mention id="M708" type="Trigger" span="98 18;130 6" str="increase in trough | levels"/>
<Mention id="M709" type="Precipitant" span="117 12" str="cyclosporine" code="83HN0GTJ6D"/>
<Interaction id="I246" type="Pharmacokinetic interaction" trigger="M708" precipitant="M709" effect="C54357"/>
</Sentence>
<Sentence id="2055" LabelDrug="Caduet" section="34090-1">
<SentenceText>Tacrolimus: A prospective study in healthy Chinese volunteers (N=9) with CYP3A5 expressers showed a 2.5- to 4-fold increase in tacrolimus exposure when concomitantly administered with amlodipine compared to tacrolimus alone.</SentenceText>
<Mention id="M710" type="Trigger" span="115 8;138 8" str="increase | exposure"/>
<Mention id="M711" type="Precipitant" span="127 10" str="tacrolimus" code="WM0HAQ4WNM"/>
<Interaction id="I247" type="Pharmacokinetic interaction" trigger="M710" precipitant="M711" effect="C54357"/>
</Sentence>
<Sentence id="2056" LabelDrug="Caduet" section="34090-1">
<SentenceText>This finding was not observed in CYP3A5 non-expressers (N= 6).</SentenceText>
</Sentence>
<Sentence id="2057" LabelDrug="Caduet" section="34090-1">
<SentenceText>However, a 3-fold increase in plasma exposure to tacrolimus in a renal transplant patient (CYP3A5 non-expresser) upon initiation of amlodipine for the treatment of post-transplant hypertension resulting in reduction of tacrolimus dose has been reported.</SentenceText>
<Mention id="M712" type="Trigger" span="18 27" str="increase in plasma exposure "/>
<Mention id="M713" type="Trigger" span="206 12;230 4" str=" reduction of | dose"/>
<Mention id="M714" type="Precipitant" span="49 10" str="tacrolimus" code="WM0HAQ4WNM"/>
<Interaction id="I248" type="Pharmacokinetic interaction" trigger="M712;M713" precipitant="M714" effect="C54357"/>
</Sentence>
<Sentence id="2058" LabelDrug="Caduet" section="34090-1">
<SentenceText>Irrespective of the CYP3A5 genotype status, the possibility of an interaction cannot be excluded with these drugs.</SentenceText>
</Sentence>
<Sentence id="2059" LabelDrug="Caduet" section="34090-1">
<SentenceText>Atorvastatin: Table 5 shows the effects of atorvastatin on the pharmacokinetics of other drugs.</SentenceText>
</Sentence>
<Sentence id="2060" LabelDrug="Caduet" section="34090-1">
<SentenceText>Effect of Atorvastatin on the Pharmacokinetics of Co-administered Drugs Atorvastatin Co-administered drug and dosing regimen Drug/Dose (mg) Change in AUC Change in Cmax 80 mg QD for 15 days Antipyrine, 600 mg SD ↑ 3% ↓ 11% 80 mg QD for 14 days Digoxin 0.25 mg QD, 20 days ↑ 15% ↑ 20 % 40 mg QD for 22 days Oral contraceptive QD, 2 months – norethindrone 1mg– ethinyl estradiol 35 µg ↑ 28%↑ 19% ↑ 23%↑ 30% 10 mg, SD Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days No change No change 10 mg QD for 4 days Fosamprenavir 1400 mg BID, 14 days ↓ 27% ↓ 18% 10 mg QD for 4 days Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days No change No change</SentenceText>
</Sentence>
</Sentences>
<LabelInteractions><LabelInteraction type="Pharmacodynamic interaction" precipitant="fibrates" precipitantCode="6848ST447Q" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="clarithromycin" precipitantCode="H1250JIK0A" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="clarithromycin" precipitantCode="H1250JIK0A" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="clarithromycin" precipitantCode="H1250JIK0A" effect="13791008:  Asthenia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="clarithromycin" precipitantCode="H1250JIK0A" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="clarithromycin" precipitantCode="H1250JIK0A" effect="247348008: Tenderness (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="clarithromycin" precipitantCode="H1250JIK0A" effect="68962001: Muscle pain (finding)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="clarithromycin" precipitantCode="H1250JIK0A" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="clarithromycin" precipitantCode="H1250JIK0A" effect="C54605"/>
<LabelInteraction type="Unspecified interaction" precipitant="clarithromycin" precipitantCode="H1250JIK0A"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyclosporine" precipitantCode="83HN0GTJ6D" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyclosporine" precipitantCode="83HN0GTJ6D" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyclosporine" precipitantCode="83HN0GTJ6D" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyclosporine" precipitantCode="83HN0GTJ6D" effect="NO MAP"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyclosporine" precipitantCode="83HN0GTJ6D" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyclosporine" precipitantCode="83HN0GTJ6D" effect="C54357"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyclosporine" precipitantCode="83HN0GTJ6D" effect="C54605"/>
<LabelInteraction type="Unspecified interaction" precipitant="cyclosporine" precipitantCode="83HN0GTJ6D"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="hepatitis c protease inhibitor" precipitantCode="N0000182639" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="hepatitis c protease inhibitor" precipitantCode="N0000182639" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="hepatitis c protease inhibitor" precipitantCode="N0000182639" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="hepatitis c protease inhibitor" precipitantCode="N0000182639" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="hepatitis c protease inhibitor" precipitantCode="N0000182639" effect="C54605"/>
<LabelInteraction type="Unspecified interaction" precipitant="hepatitis c protease inhibitor" precipitantCode="N0000182639"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="hiv protease inhibitors" precipitantCode="N0000000246" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="hiv protease inhibitors" precipitantCode="N0000000246" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="hiv protease inhibitors" precipitantCode="N0000000246" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="hiv protease inhibitors" precipitantCode="N0000000246" effect="C54355"/>
<LabelInteraction type="Unspecified interaction" precipitant="hiv protease inhibitors" precipitantCode="N0000000246"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="itraconazole" precipitantCode="304NUG5GF4" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="itraconazole" precipitantCode="304NUG5GF4" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="itraconazole" precipitantCode="304NUG5GF4" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="itraconazole" precipitantCode="304NUG5GF4" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="itraconazole" precipitantCode="304NUG5GF4" effect="C54605"/>
<LabelInteraction type="Unspecified interaction" precipitant="itraconazole" precipitantCode="304NUG5GF4"/>
<LabelInteraction type="Unspecified interaction" precipitant="protease inhibitors" precipitantCode="N0000175889"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="telaprevir" precipitantCode="655M5O3W0U" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="telaprevir" precipitantCode="655M5O3W0U" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="telaprevir" precipitantCode="655M5O3W0U" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="telaprevir" precipitantCode="655M5O3W0U" effect="C54605"/>
<LabelInteraction type="Unspecified interaction" precipitant="telaprevir" precipitantCode="655M5O3W0U"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="tipranavir plus ritonavir" precipitantCode="NO MAP" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="tipranavir plus ritonavir" precipitantCode="NO MAP" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="tipranavir plus ritonavir" precipitantCode="NO MAP" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="tipranavir plus ritonavir" precipitantCode="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="lopinavir plus ritonavir" precipitantCode="NO MAP" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="lopinavir plus ritonavir" precipitantCode="NO MAP" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="lopinavir plus ritonavir" precipitantCode="NO MAP" effect="13791008:  Asthenia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="lopinavir plus ritonavir" precipitantCode="NO MAP" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="lopinavir plus ritonavir" precipitantCode="NO MAP" effect="247348008: Tenderness (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="lopinavir plus ritonavir" precipitantCode="NO MAP" effect="68962001: Muscle pain (finding)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="lopinavir plus ritonavir" precipitantCode="NO MAP" effect="C54355"/>
<LabelInteraction type="Unspecified interaction" precipitant="lopinavir plus ritonavir" precipitantCode="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="darunavir plus ritonavir" precipitantCode="NO MAP" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="darunavir plus ritonavir" precipitantCode="NO MAP" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="darunavir plus ritonavir" precipitantCode="NO MAP" effect="13791008:  Asthenia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="darunavir plus ritonavir" precipitantCode="NO MAP" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="darunavir plus ritonavir" precipitantCode="NO MAP" effect="247348008: Tenderness (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="darunavir plus ritonavir" precipitantCode="NO MAP" effect="68962001: Muscle pain (finding)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="darunavir plus ritonavir" precipitantCode="NO MAP" effect="C54355"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fosamprenavir" precipitantCode="WOU1621EEG" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fosamprenavir" precipitantCode="WOU1621EEG" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fosamprenavir" precipitantCode="WOU1621EEG" effect="13791008:  Asthenia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fosamprenavir" precipitantCode="WOU1621EEG" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fosamprenavir" precipitantCode="WOU1621EEG" effect="247348008: Tenderness (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fosamprenavir" precipitantCode="WOU1621EEG" effect="68962001: Muscle pain (finding)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="fosamprenavir" precipitantCode="WOU1621EEG" effect="C54355"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fosamprenavir plus ritonavir" precipitantCode="NO MAP" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fosamprenavir plus ritonavir" precipitantCode="NO MAP" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fosamprenavir plus ritonavir" precipitantCode="NO MAP" effect="13791008:  Asthenia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fosamprenavir plus ritonavir" precipitantCode="NO MAP" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fosamprenavir plus ritonavir" precipitantCode="NO MAP" effect="247348008: Tenderness (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fosamprenavir plus ritonavir" precipitantCode="NO MAP" effect="68962001: Muscle pain (finding)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="fosamprenavir plus ritonavir" precipitantCode="NO MAP" effect="C54355"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="saquinavir plus ritonavir" precipitantCode="NO MAP" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="saquinavir plus ritonavir" precipitantCode="NO MAP" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="saquinavir plus ritonavir" precipitantCode="NO MAP" effect="13791008:  Asthenia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="saquinavir plus ritonavir" precipitantCode="NO MAP" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="saquinavir plus ritonavir" precipitantCode="NO MAP" effect="247348008: Tenderness (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="saquinavir plus ritonavir" precipitantCode="NO MAP" effect="68962001: Muscle pain (finding)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="saquinavir plus ritonavir" precipitantCode="NO MAP" effect="C54355"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="boceprevir" precipitantCode="89BT58KELH" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="boceprevir" precipitantCode="89BT58KELH" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="boceprevir" precipitantCode="89BT58KELH" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="boceprevir" precipitantCode="89BT58KELH" effect="C54355"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="hiv protease inhibitor" precipitantCode="N0000000246" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="hiv protease inhibitor" precipitantCode="N0000000246" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="hiv protease inhibitor" precipitantCode="N0000000246" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="hiv protease inhibitor" precipitantCode="N0000000246" effect="C54355"/>
<LabelInteraction type="Unspecified interaction" precipitant="hiv protease inhibitor" precipitantCode="N0000000246"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nelfinavir" precipitantCode="HO3OGH5D7I" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nelfinavir" precipitantCode="HO3OGH5D7I" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nelfinavir" precipitantCode="HO3OGH5D7I" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="nelfinavir" precipitantCode="HO3OGH5D7I" effect="C54355"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="lipid-lowering medications" precipitantCode="NO MAP" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="lipid-lowering medications" precipitantCode="NO MAP" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="ethinyl estradiol" precipitantCode="423D2T571U" effect="C54357"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="ethinyl estradiol" precipitantCode="423D2T571U" effect="C54613"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="norethindrone" precipitantCode="T18F433X4S" effect="C54357"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="norethindrone" precipitantCode="T18F433X4S" effect="C54613"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="oral contraceptives" precipitantCode="NO MAP" effect="C54357"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyp3a inhibitors" precipitantCode="N0000191001" effect="267038008: Edema (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyp3a inhibitors" precipitantCode="N0000191001" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyp3a inhibitors" precipitantCode="N0000191001" effect="C54355"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyp3a inducers" precipitantCode="N0000190118" effect="38936003: Abnormal blood pressure (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="sildenafil" precipitantCode="3M7OB98Y7H" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="tacrolimus" precipitantCode="WM0HAQ4WNM" effect="NO MAP"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="tacrolimus" precipitantCode="WM0HAQ4WNM" effect="C54357"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fibric acid derivatives" precipitantCode="6848ST447Q" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fibric acid derivatives" precipitantCode="6848ST447Q" effect="13791008:  Asthenia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fibric acid derivatives" precipitantCode="6848ST447Q" effect="247348008: Tenderness (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fibric acid derivatives" precipitantCode="6848ST447Q" effect="68962001: Muscle pain (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="lipid-modifying doses of niacin" precipitantCode="2679MF687A" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="lipid-modifying doses of niacin" precipitantCode="2679MF687A" effect="13791008:  Asthenia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="lipid-modifying doses of niacin" precipitantCode="2679MF687A" effect="247348008: Tenderness (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="lipid-modifying doses of niacin" precipitantCode="2679MF687A" effect="68962001: Muscle pain (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="strong cyp3a4 inhibitors" precipitantCode="N0000182141" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="strong cyp3a4 inhibitors" precipitantCode="N0000182141" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="strong cyp3a4 inhibitors" precipitantCode="N0000182141" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="strong inhibitors of cyp3a4" precipitantCode="N0000182141" effect="C54355"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="combinations of hiv protease inhibitors" precipitantCode="N0000000246" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="combinations of hiv protease inhibitors" precipitantCode="N0000000246" effect="C54605"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="hepatitis c protease inhibitor telaprevir" precipitantCode="655M5O3W0U" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="hepatitis c protease inhibitor telaprevir" precipitantCode="655M5O3W0U" effect="C54605"/>
<LabelInteraction type="Unspecified interaction" precipitant="hepatitis c protease inhibitor telaprevir" precipitantCode="655M5O3W0U"/>
<LabelInteraction type="Unspecified interaction" precipitant="hiv protease inhibitor tipranavir plus ritonavir" precipitantCode="NO MAP"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="hiv protease inhibitor lopinavir plus ritonavir" precipitantCode="NO MAP" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="hiv protease inhibitors saquinavir plus ritonavir" precipitantCode="NO MAP" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="hepatitis c protease inhibitor boceprevir" precipitantCode="89BT58KELH" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="hiv protease inhibitor nelfinavir" precipitantCode="HO3OGH5D7I" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="components that inhibit cyp3a4" precipitantCode="N0000182141" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="excessive grapefruit juice" precipitantCode="JQ9EK2H6BG" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="inhibitors of the oatp1b1" precipitantCode="NO MAP" effect="C54355"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="gemfibrozil" precipitantCode="Q8X02027X3" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="gemfibrozil" precipitantCode="Q8X02027X3" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="gemfibrozil" precipitantCode="Q8X02027X3" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="niacin" precipitantCode="2679MF687A" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="niacin" precipitantCode="2679MF687A" effect="75047002: Disorder of skeletal muscle (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="niacin" precipitantCode="2679MF687A" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="efavirenz" precipitantCode="JE6H2O27P8" effect="C54356"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="inducers of cyp3a4" precipitantCode="N0000185506" effect="C54356"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="rifampin" precipitantCode="VJT6J7R4TR" effect="C54356"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="digoxin" precipitantCode="73K4184T59" effect="C54357"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="colchicine" precipitantCode="SML2Y3J35T" effect=" 240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="colchicine" precipitantCode="SML2Y3J35T" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="colchicine" precipitantCode="SML2Y3J35T" effect="240131006: Rhabdomyolysis (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="azole antifungals" precipitantCode="N0000175487" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="azole antifungals" precipitantCode="N0000175487" effect="13791008:  Asthenia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="azole antifungals" precipitantCode="N0000175487" effect="247348008: Tenderness (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="azole antifungals" precipitantCode="N0000175487" effect="68962001: Muscle pain (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="erythromycin" precipitantCode="63937KV33D" effect="129565002: Disorder of skeletal AND/OR smooth muscle (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="erythromycin" precipitantCode="63937KV33D" effect="13791008:  Asthenia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="erythromycin" precipitantCode="63937KV33D" effect="247348008: Tenderness (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="erythromycin" precipitantCode="63937KV33D" effect="68962001: Muscle pain (finding)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="erythromycin" precipitantCode="63937KV33D" effect="C54355"/>
<LabelInteraction type="Unspecified interaction" precipitant="cimetidine" precipitantCode="80061L1WGD"/>
<LabelInteraction type="Unspecified interaction" precipitant="drugs that may decrease the levels or activity of endogenous steroid hormones" precipitantCode="NO MAP"/>
<LabelInteraction type="Unspecified interaction" precipitant="ketoconazole" precipitantCode="R9400W927I"/>
<LabelInteraction type="Unspecified interaction" precipitant="spironolactone" precipitantCode="27O7W4T232"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="food" precipitantCode="NO MAP" effect="C54356"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="diltiazem" precipitantCode="EE92BBP03H" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="strong inhibitors of cyp3a" precipitantCode="N0000191001" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="excessive grapefruit" precipitantCode="O82C39RR8C" effect="C54605"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyp3a substrates" precipitantCode="NO MAP" effect="C54357"/>

</LabelInteractions></Label>